File Name,Identity of Submitting Entity,Representation Details,Cited Statutes or Regulations,FDA Action Commented On,Requested Action,Justification for Request,Date of Petition
FDA-2013-P-0025-0001_Citizen_Petition_from_Teva_Pharmaceutical_Industri.pdf,"Teva Pharmaceutical Industries Ltd. and Teva Neuroscience, Inc.",No,"21 C.F.R. § 10.30, 21 U.S.C. § 355(b), 21 U.S.C. § 355(s)",The petitioner is commenting on FDA’s process of approving new drugs for the treatment of multiple sclerosis (MS) without prior review by the Peripheral and Central Nervous System Advisory Committee (PCNS Advisory Committee).,"The petitioner requests that FDA refrain from approving any full New Drug Application (NDA) or Biologics License Application (BLA) for new MS treatments unless and until the FDA has referred the product to, and considered the recommendations of, the PCNS Advisory Committee.","The petitioner justifies the request by arguing that MS is a complex, immune-mediated disorder, and serious safety issues with new MS treatments (e.g., Tysabri, Gilenya) were identified only after widespread use. Therefore, advisory committee review is necessary to thoroughly evaluate the risks and benefits of new MS drugs before approval, in line with statutory requirements and to protect public health.","Printed December 31, 2012; Stamped nan"
FDA-2013-P-0027-0001_Custo_Pharm_Inc__Citizen_Petiton.pdf,"Custo Pharm, Inc.",No,"21 C.F.R. § 10.20, 21 C.F.R. § 10.30, 21 C.F.R. § 314.93, 21 C.F.R. § 25.31",The petitioner is commenting on the need to update the FDA’s Orange Book listing to establish a new Reference Listed Drug (RLD) for Midodrine Hydrochloride Tablets following the discontinuation of Proamatine (NDA 19815).,"The petitioner requests that the FDA designate Impax Pharmaceutical’s Midodrine Hydrochloride Tablets, ANDA 076449, as the RLD to facilitate the submission of ANDAs for generic versions of Midodrine Hydrochloride Tablets.","The petitioner justifies the request by stating that the original RLD, Proamatine, has been discontinued, and among the current products on the market, Impax's product was the first approved ANDA and remains available. Without designating a new RLD, the market would be shielded from generic competition, limiting availability and access to Midodrine Hydrochloride Tablets.","Printed Printed December 28, 2012; Stamped Stamped December 31, 2012"
FDA-2013-P-0028-0001_Custo_Pharm_Inc_Citizen_Petition.pdf,"Custo Pharm, Inc.",No,"21 C.F.R. § 10.20, 21 C.F.R. § 10.30, 21 C.F.R. § 314.93, 21 C.F.R. § 25.31","The petitioner is commenting on the FDA’s Orange Book listings, specifically on the establishment of a second reference listed drug (RLD) for Clotrimazole Troche/Lozenge 10 mg.","The petitioner requests that the FDA designate Roxane’s Clotrimazole Troche, ANDA 076387, as a second RLD for the purpose of facilitating the submission of ANDAs for a generic version of Clotrimazole Troche.","The petitioner justifies the request by explaining that Bayer’s Mycelex Troche (the current RLD) has been unavailable in the U.S. for many months. Without a second RLD designation, the product could be shielded from generic competition, thus limiting access to generic alternatives.","Printed Printed December 28, 2012; Stamped Stamped December 31, 2012"
FDA-2013-P-0040-0001_Lupin_Pharmaceuticals_Inc_Citizen_Petition.pdf,"Lupin Pharmaceuticals, Inc.",No,"21 C.F.R. § 10.30, 21 C.F.R. § 314.94, 21 C.F.R. § 25.31","The petitioner is commenting on the FDA’s Orange Book listing for Calcium Acetate Capsules, specifically regarding the designation of a Reference Listed Drug (RLD) after the original RLD (PHOSLO Capsules) became unavailable in the market.",The petitioner requests that the FDA amend the Orange Book to designate Roxane’s Calcium Acetate Capsules as the new Reference Listed Drug (RLD) for Calcium Acetate Capsules.,"The petitioner justifies the request by explaining that PHOSLO Capsules are no longer available in the market since November 2012, and Roxane’s Calcium Acetate Capsules are approved, rated AB (bioequivalent), and are currently marketed. Designating Roxane’s product as the RLD would facilitate the continued availability of generic Calcium Acetate products.","Printed nan; Stamped Stamped Jan 3, 2013"
FDA-2013-P-0047-0001_American_Heart_Association_AHA_Health_Claim_Petiti.pdf,The American Heart Association,No,"21 C.F.R. § 101.70, 21 C.F.R. § 101.75",The petitioner is commenting on the FDA’s health claim regulation regarding dietary saturated fat and cholesterol and their relationship to the risk of coronary heart disease.,The petitioner requests that FDA amend the existing health claim regulation at 21 C.F.R. § 101.75 to update the scientific basis and wording of the claim regarding the relationship between dietary saturated fat and cholesterol intake and the risk of coronary heart disease.,"The petitioner justifies the request by citing advances in scientific understanding since the original regulation was established, arguing that current scientific evidence warrants an updated health claim to better inform consumers about the relationship between diet and heart disease risk.","Printed September 28, 2012; Stamped nan"
FDA-2013-P-0048-0001_James_P_Reichmann_Citizen_Petition_Redacted.pdf,James P. Reichmann,No,"21 U.S.C. § 355(e)(3), 21 C.F.R. § 10.30",The petitioner is commenting on the FDA’s classification and regulatory approach regarding the pregnancy risk categorization and off-label promotion of ondansetron (Zofran®) for nausea and vomiting of pregnancy (NVP).,"The petitioner requests that FDA (1) reclassify ondansetron from pregnancy risk category B to category C, D, or X, and (2) notify OB/GYNs that ondansetron has not been proven effective for NVP and that promoting its use via subcutaneous pump without FDA approval violates regulations.","The petitioner justifies the request by citing limited efficacy evidence, concerns over fetal safety (including a reported increased risk of cleft palate), and FDA warnings about serious cardiac side effects (QT prolongation) associated with ondansetron, particularly with higher doses common in subcutaneous pump use.","Printed Printed January 4, 2012; Stamped Stamped January 7, 2013"
FDA-2013-P-0058-0001_Gilead_Sciences_Inc_Hogan_Lovells_US_LLP_Citizen_P.pdf,"Gilead Sciences, Inc.",Represented by Hogan Lovells US LLP,"21 C.F.R. 10.30, 21 U.S.C. 355(c)(3)(E)(ii), 21 U.S.C. 355(j)(5)(F)(ii), Hatch-Waxman Act",FDA's historical interpretation of 5-year exclusivity provisions denying exclusivity to fixed dose combinations (FDCs) containing new active moieties with previously approved moieties,Recognize 5-year exclusivity under sections 505(c)(3)(E)(ii) and 505(j)(5)(F)(ii) for each new active moiety in STRIBILD (EVG and COBI); revise FDA’s Exclusivity Summary and related documents to reflect this interpretation,"FDA’s historical interpretation is outdated, inconsistent with modern medical practice (especially in treating HIV with FDCs), not mandated by statute or regulation, leads to arbitrary results, and discourages innovation in developing fixed-dose combination therapies; administrative law permits FDA to change its interpretation without formal rulemaking.","Printed January 8, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-0066-0001_Pharmacists_Planning_Services_Inc_Citizen_Petition.pdf,"Pharmacists Planning Services, Inc. (PPSI)",No,"21 C.F.R. § 10.20, 21 C.F.R. § 10.30, Federal Food, Drug, and Cosmetic Act","The petitioner is commenting on the FDA's regulation of dietary supplements, specifically requesting action on St. John's Wort (SJW) (Hypericum perforatum) by reclassifying it from a dietary supplement to a drug placed behind the pharmacy counter.","The petitioner requests that FDA remove St. John's Wort from Herbal Dietary Supplement status and reclassify it as a Behind Pharmacy Counter Status (BPCS) drug requiring mandatory consultation, patient history review, identification, and registration.","The petitioner justifies the request by citing numerous drug interactions associated with St. John's Wort, adverse effects like vivid dreams, anxiety, and fatigue, evidence of bans or restrictions in other countries (France, Ireland, Germany), public health risks, poor patient awareness from package inserts, and concerns from professional organizations about the widespread unregulated use of herbal supplements.","Printed Printed January 9, 2013; Stamped Stamped January 14, 2013"
FDA-2013-P-0070-0001_Exhibit_A_Letter_to_Robert_Outwater_Ohmeda_Inc_Fro.pdf,"Ikaria, Inc.",No,"21 C.F.R. § 10.30, Section 505(i) of the Federal Food, Drug, and Cosmetic Act","The petitioner is commenting on the regulatory approval and classification of inhaled nitric oxide (INO) products and devices, based on communications between Ohmeda Inc. and the FDA related to clinical development and regulatory approval pathways.","The petitioner requests that FDA regulate all inhaled nitric oxide drug products and delivery systems under the drug authorities, ensuring that new nitric oxide systems are reviewed and approved through appropriate drug application processes, not solely device pathways.","The petitioner justifies the request by emphasizing that inhaled nitric oxide is a drug requiring rigorous clinical testing, highlighting safety concerns related to gas exposure to patients and healthcare workers, and stressing that regulatory precedent (as seen with Ohmeda’s development) treated inhaled nitric oxide as a drug requiring an NDA supported by clinical trials and toxicology studies.","Printed nan; Stamped Stamped Aug 23, 1994 and Aug 25, 1994"
FDA-2013-P-0076-0001_Minnesota_Medical_Device_Alliance_MMDA_DuVal_and_A.pdf,"DuVal & Associates, P.A.",Representing Minnesota Medical Device Alliance (MMDA),"21 C.F.R. § 10.30, 21 C.F.R. § 10.35, 21 U.S.C. § 360k, 21 C.F.R. §§ 807 Subpart E","Evaluating Substantial Equivalence in Premarket Notifications [510(k)], dated December 27, 2011","Stay implementation of the New 510(k) Guidance, revert to existing 510(k) guidance documents, cease 'stage-gated' reviews, improve training and education for FDA staff, and establish regular dialogue sessions between FDA and industry groups","The petitioner argues that FDA's new practices have altered the 510(k) program without legislative authority, increased regulatory burdens, delayed patient access to innovations, harmed investment and innovation in the U.S. medical device industry, and that FDA has become overly risk-averse, ignoring Least Burdensome requirements and deviating from statutory and regulatory mandates.","Printed Printed January 2, 2013; Stamped Stamped January 16, 2013"
FDA-2013-P-0113-0001_IGI_Laboratories_Inc_Citizen_Petition.pdf,"IGI Laboratories, Inc.",No,"21 U.S.C. § 355, 21 C.F.R. § 314.93, 21 C.F.R. § 314.161","The petitioner is commenting on the FDA's determination regarding whether Cordran (flurandrenolide) Ointment USP, 0.05% was withdrawn from sale for reasons of safety or effectiveness.","The petitioner requests that the FDA determine that Cordran (flurandrenolide) Ointment USP, 0.05% was not withdrawn from sale for reasons of safety or effectiveness.","The petitioner justifies the request by stating that Cordran Ointment was voluntarily discontinued for commercial reasons, not for safety or efficacy concerns. Other formulations of the same active ingredient (Cordran creams and lotion) are still actively marketed, and references to the ointment remain in updated labeling materials, suggesting no underlying safety or effectiveness issues.","Printed Printed January 15, 2013; Stamped Stamped January 28, 2013"
FDA-2013-P-0127-0001_Santarus_Inc_Citizen_Petition.pdf,"Santarus, Inc.",No representation; Santarus submitted the petition on its own behalf,"Section 505 of the FD&C Act, 21 C.F.R. § 10.30, 21 C.F.R. § 320.24, 21 U.S.C. § 355(j)(8)(C), 21 C.F.R. §§ 25.30 and 25.31",Approval of abbreviated new drug applications (ANDAs) citing Uceris (budesonide) extended release tablets as the reference listed drug without appropriate bioequivalence studies,"Develop and publish a product-specific bioequivalence recommendation for budesonide extended release tablets (Uceris) and refrain from approving any ANDA for Uceris until generics demonstrate bioequivalence through specific studies including clinical endpoint studies, alternative PK testing, in vitro dissolution testing at multiple pHs, and pharmacoscintigraphy studies","Santarus argues that Uceris has unique delivery properties critical to its safety and efficacy (colon-targeted, extended release), and that standard bioequivalence testing methods (relying solely on PK measures) are inadequate. They request enhanced testing requirements to ensure generics match Uceris in delivering budesonide throughout the colon to treat ulcerative colitis effectively.","Printed February 1, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-0148-0001_Crowell_and_Moring_LLP_Citizen_Petition.pdf,Crowell & Moring LLP,No representation of another entity explicitly mentioned; the firm submitted on its own behalf,"21 U.S.C. § 301 et seq. (FDCA), 21 C.F.R. § 10.30, 21 C.F.R. § 25.31(a)",FDA’s adoption and Orange Book listing of the strength for Lovaza (omega-3-acid ethyl esters) Capsules,"Amend the strength listing for Lovaza to identify only the amount of active ingredient per administration unit (either 0.9GM or 900MG), removing reference to product weight, excipients, or inactive ingredients","Petitioner argues that FDA’s current listing deviates from the established regulatory framework where strength identifies only the active ingredient per administration unit, leading to inconsistency with thousands of other Orange Book listings, public FDA guidance, and the Lovaza labeling and drug listings; correction is necessary for regulatory consistency and clarity.","Printed February 6, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-0163-0001_Teva_Womens_Health_Inc_Citizen_Petition.pdf,"Teva Women's Health, Inc.","Teva Women's Health, Inc. is a subsidiary representing Teva Pharmaceutical Industries Ltd.","21 C.F.R. § 10.30, 21 U.S.C. § 355(j), 21 C.F.R. § 884.5360, 21 C.F.R. § 310.502(a)(8)",Approval of Abbreviated New Drug Applications (ANDAs) referencing ParaGard T 380A intrauterine copper contraceptive,"(1) comparative clinical trials establishing bioequivalence, (2) identical labeling to ParaGard, and (3) identical physical components to ParaGard","Justifications include that ParaGard acts locally with mechanisms not fully understood, copper and non-copper components contribute to efficacy, and minor changes could significantly affect safety and efficacy; therefore, clinical trials, identical labeling, and device component identity are necessary to ensure generic equivalence and public health protection","Printed February 11, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-0170-0001_Clinipace_Worldwide_Citizen_Petition.pdf,Clinipace Worldwide,No,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. § 10.20; 21 C.F.R. § 10.30; 21 C.F.R. § 314.93; 21 C.F.R. § 25.31",FDA’s regulation allowing submission of abbreviated new drug applications (ANDAs) for strengths different from reference listed drugs (RLDs),"The petitioner requests FDA to declare that hydroxychloroquine sulfate tablets in 100 mg, 300 mg, and 400 mg strengths are suitable for submission and review under an ANDA referencing Plaquenil (hydroxychloroquine sulfate) 200 mg tablets as the RLD.","The petitioner justifies the request by explaining that the proposed new strengths will provide convenient alternative dosing options for both adults and pediatric patients, match labeled dosing flexibility outlined in the RLD, and do not raise new safety or efficacy issues since they align with already approved dosing regimens; also, no new active ingredient, indication, dosage form, dosing regimen, or route of administration is involved, making Pediatric Research Equity Act (PREA) obligations inapplicable.","Printed Printed February 11, 2013; Stamped Stamped February 12, 2013"
FDA-2013-P-0198-0001_Takeda_Pharmaceuticals_USA_Inc_Citizen_Petition.pdf,"Takeda Pharmaceuticals U.S.A., Inc.",Not Mentioned,"21 U.S.C. 355, 21 C.F.R. 10.30",Approval of abbreviated new drug applications (ANDAs) referencing DEXILANT (dexlansoprazole) delayed-release capsules,"Refrain from approving any ANDA referencing DEXILANT unless it includes data showing bioequivalence using partial AUC metrics in addition to conventional metrics (AUC₀₋ₜ, AUC₀₋∞, and Cₘₐₓ).","The petitioner argues that DEXILANT is a dual delayed-release product with biphasic pharmacokinetics and that the existing FDA draft guidance does not require partial AUC metrics necessary to ensure therapeutic equivalence of generics. Without additional metrics such as pAUC₀₋₂ₕ and pAUC₂₋₁₀ₕ, a generic may not truly replicate the dual-release profile essential for safety and efficacy.","Printed February 15, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-0199-0001_Richard_M_Karcich_Citizen_Petition_Redacted.pdf,Richard M. Karcich,No,"General Principles of Software Validation; Final Guidance for Industry and FDA Staff Section 6.1, FDA Quality System Regulations, Medical Device Directive, ISO 13485, ISO 14971, IEC 62366, IEC 62304","FDA's current regulatory approach to software validation for medical devices, which leaves validation practices largely at the discretion of device manufacturers",Request for FDA to issue new regulations or amend existing regulations to require measurement of code change activity and test activity as a mandatory part of software fault management for medical device software,"Petitioner argues that current FDA regulations result in inadequate accountability and allow software faults to escape detection, leading to patient risk. By adopting mandatory measurement practices, device manufacturers can better manage software safety and reliability, detect faults early, and prevent life-threatening failures such as those implicated in Class I medical device recalls.","Printed Stamped February 15, 2013; Stamped nan"
FDA-2013-P-0203-0001_Merchant_Gould_PC_Citizen_Petition.pdf,Merchant & Gould P.C.,Representing an unnamed client,"21 C.F.R. §§ 10.20, 10.30, 314.99(b), 314.94(a)(9)(iii), 314.127(a)(8)(ii)(B), 314.90, 505(j) of the FDCA",Enforcement of the requirement for identical inactive ingredients in parenteral drug products under 21 CFR 314.94(a)(9)(iii) and 314.127(a)(8)(ii)(B),Request to waive enforcement of the requirement that the ANDA for Voriconazole for Injection 200 mg/vial have identical inactive ingredients to the reference listed drug (Vfend®); specifically to allow use of hydroxypropyl β-cyclodextrin instead of sulfobutyl ether β-cyclodextrin sodium,"Petition argues that the substituted excipient (hydroxypropyl β-cyclodextrin) is safe, has similar pharmacokinetics and toxicity profile to the original excipient, and that the change would not affect the safety or efficacy of the drug product; also, historical precedent exists where FDA approved similar requests for changes in inactive ingredients in parenteral drugs","Printed Printed February 15, 2013; Stamped Stamped February 19, 2013 "
FDA-2013-P-0204-0001_Chrai_Associates_Inc_on_behalf_of_Square_Pharmaceu.pdf,"Chrai Associates, Inc. on behalf of Square Pharmaceuticals Ltd.","Chrai Associates, Inc. representing Square Pharmaceuticals Ltd.","21 C.F.R. § 10.30, Section 101 of the Generic Drug User Fee Amendments of 2012 (GDUFA)",FDA’s implementation of the Generic Drug User Fee Act (GDUFA) requiring annual Finished Dosage Form (FDF) facility fees for manufacturers with pending ANDAs,"The petitioner requests that FDA amend, clarify, or revise the GDUFA regulation to require a one-time FDF facility fee payment upon ANDA approval or commercialization instead of annual fees before approval; and requests that FDA exempt the client from paying annual FDF facility fees until a decision on the petition is made.","The petitioner argues that charging annual facility fees before product approval imposes an unfair financial burden on small or first-time foreign manufacturers without U.S. market revenue, contradicts fairness principles compared to PDUFA practices, and may stifle entry of generic products. They propose a one-time fee model similar to European practices to cover necessary FDA regulatory expenses.","Printed Printed February 13, 2013; Stamped Stamped February 14, 2013"
FDA-2013-P-0217-0001_Center_for_Science_in_the_Public_Interest_Citizen_.pdf,Center for Science in the Public Interest (CSPI),Not Mentioned,"21 C.F.R. § 10.30, 21 C.F.R. § 184.1854, 21 C.F.R. § 184.1857, 21 C.F.R. § 184.1859, 21 C.F.R. § 184.1865, 21 C.F.R. § 184.1866, 21 U.S.C. § 321(s), 21 U.S.C. § 348(a), 21 C.F.R. § 170.3(i), 21 C.F.R. § 170.30, 21 C.F.R. § 170.6(c), 21 C.F.R. § 170.300, 21 C.F.R. § 184.1(b)(2), 21 C.F.R. § 181.1(b)","GRAS status of added sugars (sucrose, high-fructose corn syrup, corn sugar, invert sugar, corn syrup) and their regulation in beverages and foods","Initiate rule-making to limit safe levels of sucrose and HFCS in beverages, amend Nutrition Facts to specify 'added sugars', set lower targets for added sugars in foods, conduct public education campaigns, and work with industry to reduce added sugars","Overconsumption of added sugars contributes to obesity, cardiovascular disease, diabetes, gout, dental caries, and poor nutrition; evidence since original GRAS determinations shows current consumption levels are unsafe, necessitating regulatory action to protect public health","Printed Printed February 13, 2013; Stamped Stamped February 20, 2013"
FDA-2013-P-0219-0001_International_Isotopes_Inc_I3_Citizen_Petition.pdf,"International Isotopes, Inc.",No,Not explicitly cited beyond referencing suitability petition standards; general reliance on FDA suitability petition regulations (21 C.F.R. § 314.93 implied),"Approval of ANDA suitability petition to allow change in strength and formulation of sodium iodide I-131 oral solution and kit components relative to the reference listed drug (HICON, NDA 021305)",Approve a suitability petition permitting an increase in the strength of sodium iodide I-131 solution from 250–1000 mCi/mL to 500–3500 mCi/mL and a change in formulation buffer components for a proposed generic product,"The proposed increase in strength will reduce the number of capsules required for dosing, simplify preparation by healthcare providers, maintain the same therapeutic agent and intended use as the reference listed drug, and the new formulation with dilute sodium hydroxide and sodium thiosulfate effectively preserves radiochemical purity without impacting patient safety or efficacy.","Printed Printed February 15, 2013; Stamped Stamped February 21, 2013"
FDA-2013-P-0228-0001_Douglas_Barasatian_Citizen_Petition_Redacted.pdf,Douglas Barasatian,No,"Federal Food, Drug, and Cosmetic Act; 21 C.F.R. § 25.31(a); 21 C.F.R. § 10.30(b)","GRAS (Generally Recognized as Safe) status of Bleached White Flour and associated bleaching agents (e.g., chlorine dioxide, benzoyl peroxide)",Remove Bleached White Flour and all chemical bleaching agents used in its production from the GRAS list and prevent its sale into the U.S. food system.,"The petitioner argues that bleaching flour introduces toxic chemicals such as Alloxan, which can destroy pancreatic cells and potentially cause diabetes. He references historical cases, scientific studies, and international regulatory differences (e.g., Europe’s ban on bleached flour) to support the claim that chemically bleached flour may be contributing to higher rates of chronic diseases in the U.S. compared to Europe.","Printed Printed February 16, 2013; Stamped Stamped February 21, 2013"
FDA-2013-P-0235-0001_Wess_E_Sharpe_Lantos_Technologies_Citizen_Petition.pdf,Wess Eric Sharpe,No,"Section 510(k) of the Federal Food, Drug, and Cosmetic Act",FDA's classification order (K121326) classifying Lantos Technologies' 3D Ear Scanner as a Class I device,Reconsider and reclassify the Lantos 3D Ear Scanner as a Class II device under product code ETY,"The petitioner argues that the Lantos 3D Ear Scanner includes a fluid-filled membrane that can create pressure within the ear canal, posing potential safety risks such as tympanic membrane rupture. This feature aligns more closely with devices classified as Class II under code ETY, rather than Class I devices under code ERA, and therefore requires stricter regulatory scrutiny to ensure patient safety.","Printed Printed February 25, 2013; Stamped Stamped February 26, 2013"
FDA-2013-P-0241-0001_Foley_Lardner_LLP_Citizen_Petition.pdf,Foley & Lardner LLP,No representation of another entity explicitly mentioned,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. §§ 10.30, 314.93, 314.161",Determination whether Cytoxan for Injection (original lyophilized powder form under NDA 12-142) was withdrawn for reasons of safety or effectiveness,"FDA should determine that Cytoxan for Injection (lyophilized powder under NDA 12-142) was not withdrawn from the market for safety or effectiveness reasons, allowing filing of an ANDA referencing the product","The petitioner states that the discontinuation of the lyophilized product was voluntary and for commercial reasons, not due to safety or efficacy issues. Previous FDA determinations found no safety/efficacy concerns for related Cytoxan formulations, and a new ANDA would enhance market competition and drug supply stability.","Printed Printed February 26, 2013; Stamped Stamped February 27, 2013"
FDA-2013-P-0247-0001_Novartis_Pharmaceuticals_Corporation_Citizen_Petit.pdf,Novartis Pharmaceuticals Corporation,No representation of another entity; submitted directly by Novartis Pharmaceuticals Corporation,"21 U.S.C. § 301 et seq. (Federal Food, Drug, and Cosmetic Act), 21 C.F.R. § 10.30, 21 U.S.C. §§ 355(j)(2)(A)(i), (v), 21 C.F.R. § 314.94(a)(8)(iv), 21 C.F.R. § 314.127(a)(7), 21 C.F.R. § 25.31(a)",Approval of ANDAs for zoledronic acid IV infusion products with carve-outs omitting protected safety and efficacy information from Reclast labeling,Request that FDA not approve any ANDA for a zoledronic acid IV infusion product that omits protected safety information from Reclast labeling and only approve ANDAs that include all protected safety information,"Omitting protected labeling would remove critical safety information necessary for safe use of zoledronic acid in treating Paget's disease patients, rendering generic versions less safe than Reclast; FDA precedents require complete labeling where omissions would impact safety across indications.","Printed Printed March 1, 2013; Stamped Stamped March 4, 2013"
FDA-2013-P-0280-0001_RJ_Reynolds_Tobacco_Company_American_Snuff_Company.pdf,"R.J. Reynolds Tobacco Company, American Snuff Company, LLC, and Santa Fe Natural Tobacco Company, Inc.",No,"Section 919 of the Federal Food, Drug, and Cosmetic Act; Family Smoking Prevention and Tobacco Control Act; 21 C.F.R. §§ 10.25, 10.30; 7 U.S.C. § 518d",FDA's method of assessing and collecting user fees for tobacco product manufacturers and importers based on market share calculations,"FDA should promulgate a regulation to ensure that no tobacco manufacturer or importer is assessed user fees greater than their actual market share percentage, requiring all manufacturers and importers to submit market sales volume data to FDA","Current market share calculations omit certain manufacturers, causing compliant companies to pay fees greater than their fair share. FDA must correct this by identifying all manufacturers/importers and including their sales volumes to ensure accurate fee assessments, especially as FDA assumes full responsibility for assessments post-2014 and expands jurisdiction to additional tobacco products.","Printed Printed March 6, 2013; Stamped Stamped March 7, 2013"
FDA-2013-P-0283-0001_Hyman_Phelps_McNamara_PC_Citizen_Petition.pdf,"Hyman, Phelps & McNamara, P.C.",Not Mentioned,"Federal Food, Drug, and Cosmetic Act (FDC Act); 21 C.F.R. § 10.30; FDC Act § 505(o)(4); 21 C.F.R. § 201.57; 21 C.F.R. § 201.56; 21 C.F.R. § 201.100; 21 C.F.R. § 202.1; 21 U.S.C. § 352(a); 21 U.S.C. § 321(n); FDC Act § 505-1","Safety concerns regarding C1 Esterase Inhibitors (Human) for the treatment of hereditary angioedema (HAE), specifically relating to risks of thromboembolic complications, infections, and device-related risks.",(1) Add boxed warnings to C1-INH products; (2) Require a REMS program; (3) Modify labeling to contraindicate use in patients with thrombosis risk; (4) Require medical supervision for use with venous access devices; (5) Require postmarketing studies.,"The petitioner argues that studies and postmarket data reveal serious risks of thrombosis and infection with C1-INH products, that current labeling and warnings are inadequate, and that increased measures are needed to ensure patient safety and informed healthcare provider decision-making.","Printed March 8, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-0291-0001_Fukushima_Fallout_Awareness_Network_Citizens_for_H.pdf,"Fukushima Fallout Awareness Network (including Ecological Options Network, Beyond Nuclear, and Citizens for Health)",No separate legal representation; these organizations are co-submitters,"21 U.S.C. §§ 321(s), 331(a), (c), & (g), 342, 346, 348, 371; 21 C.F.R. 25.30(a), (h), (j), & (k); 21 C.F.R. 25.32(a), (m), & (n)","FDA’s standards and regulatory response related to radionuclide contamination (specifically Cesium 134/137) in food, dietary supplements, and drugs following the Fukushima disaster","prohibit sale of food, dietary supplements, and drugs contaminated with more than 5 Bq/kg Cesium 134/137; require systematic testing and labeling; maintain a public database with contamination levels; prevent dilution tactics; and conduct environmental testing","Cesium 134/137 contamination poses a bioaccumulative and biomagnifying long-term health risk, no safe threshold for radiation exists according to the BEIR VII report, Fukushima continues releasing significant radiation, U.S. testing is inadequate, and consumers deserve transparency and tools to manage their exposure.","Printed Stamped March 12, 2013; Stamped nan"
FDA-2013-P-0299-0001_Trigen_Laboratories_BioKey_Inc_Citizen_Petition.pdf,"Trigen Laboratories, Inc.","BioKey, Inc. is representing Trigen Laboratories, Inc. for the petition",21 C.F.R. 10.30; 21 C.F.R. 314.94; 21 C.F.R. 25.31,FDA's designation of the Reference Listed Drug (RLD) for Bisoprolol Fumarate Tablets in the Orange Book,"Amend the Orange Book to designate a second Reference Listed Drug (RLD) for Bisoprolol Fumarate Tablets, specifically products from Sandoz and/or Mylan","TEVA Women's Zebeta® Tablets, the current RLD, are not commercially available, causing delays in the ANDA submission process; Sandoz and Mylan's products are available and meet bioequivalence standards.","Printed Printed March 4, 2013; Stamped Stamped March 13, 2013"
FDA-2013-P-0303-0001_Tedor_Pharma_Inc_Citizen_Petition.pdf,Tedor Pharma Inc.,No representation of another entity mentioned,"21 CFR §10.20, 21 CFR §10.30, 21 CFR §314.161, 21 CFR §25.31(a)",Whether Metadate® ER 10 mg (Methylphenidate Hydrochloride) Tablets (ANDA 040-306) was voluntarily withdrawn for safety or effectiveness reasons,"FDA to determine that Metadate® ER 10 mg Tablets were withdrawn for reasons unrelated to safety or effectiveness, thus allowing the filing of an ANDA for a generic version",The drug was moved to the 'Discontinued' section of the Orange Book and is unavailable in the market; the petitioner believes it was discontinued for commercial reasons rather than safety or efficacy concerns and seeks a formal determination to proceed with a generic ANDA.,"Printed Printed March 6, 2013; Stamped Stamped March 13, 2013"
FDA-2013-P-0323-0001_Cititzen_Petition_from_Rapid_Precision_Testing_Lab.pdf,Rapid Precision Testing Laboratories,No representation of another entity mentioned,"21 CFR Parts 201, 310, and 352; 58 FR 28195",FDA's ongoing review of GRASE sunscreen active ingredients and sunscreen labeling and effectiveness testing regulations,"Amend approval and formally withdraw approval of Dioxybenzone, Oxybenzone, Trolamine salicylate, Homosalate, and Octisalate as sunscreen active ingredients; reassess and amend SPF test methodology to prescreen for anti-inflammatory effects that falsely inflate SPF values","Scientific evidence showing that listed sunscreen agents act as anti-inflammatories masking erythema without preventing UV damage, concerns about misleading SPF values, potential systemic absorption risks, and possible contribution to rising skin cancer rates despite sunscreen use.","Printed Printed March 15, 2013; Stamped Stamped March 18, 2013"
FDA-2013-P-0335-0001_Foley_Lardner_LLP_Citizen_Petition.pdf,Foley & Lardner LLP,"Foley & Lardner LLP is submitting on behalf of a client, though the client's specific name is not mentioned in the text provided","Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355); 21 CFR 10.20; 21 CFR 10.30; 21 CFR 314.94; 21 CFR 320.1; 21 CFR 320.23-24; 21 CFR 25.31",FDA’s bioequivalence requirements outlined in the October 2011 Guidance for Nilutamide,"Amend the FDA's Guidance for Nilutamide to allow a single-dose, two-way crossover study in normal healthy male volunteers under specific safeguards, rather than requiring steady-state studies in patients",The proposed alternative study design minimizes risk because adverse events like hepatic injury and pneumonitis are rare and associated with chronic rather than acute exposure; similar safeguards are accepted for comparable drugs like flutamide and bicalutamide.,"Printed Printed March 14, 2013; Stamped Stamped March 15, 2013"
FDA-2013-P-0336-0001_Emcure_Pharmaceuticals_USA_Inc_Citizen_Petition.pdf,Emcure Pharmaceuticals USA Inc.,No representation of another entity mentioned,21 U.S.C. § 355(j)(2)(c); 21 CFR § 10.20; 21 CFR § 10.30; 21 CFR § 314.93; 21 CFR § 314.122; 21 CFR § 314.161; 21 CFR § 25.31(a),"Acceptance of ANDAs for Diphenhydramine Hydrochloride Injection USP, 50 mg/mL, referencing a discontinued Benadryl product","Request FDA to accept ANDAs for Diphenhydramine Hydrochloride Injection USP, 50 mg/mL (SDV and MDV) formulations equivalent to the discontinued McNeil Consumer Healthcare's Benadryl Injection","The original Benadryl Injection was discontinued for commercial reasons and not due to safety or efficacy concerns, as confirmed by FDA; therefore, the petitioner seeks approval to submit ANDAs referencing the discontinued product.","Printed March 2013 (exact day not explicitly stated, but inferred from context and typical submission timing); Stamped No Date"
FDA-2013-P-0337-0001_Hyman_Phelps_McNamara_PC_Petition_for_Stay_of_Acti.pdf,"Hyman, Phelps & McNamara, P.C.",Submitting on behalf of an unidentified client ('Company'),21 C.F.R. § 10.35; 21 C.F.R. § 10.75; 21 C.F.R. § 20.61; 21 C.F.R. § 20.47; 21 C.F.R. § 20.48; 18 U.S.C. § 1832,Decision by CDER’s Office of Manufacturing and Product Quality to deny reconsideration of issues related to a Warning Letter and plan to publish the Warning Letter,Stay publication of the Warning Letter on the FDA’s website until the appeals process is exhausted and requested redactions are reviewed and decided upon,"Premature publication would cause irreparable commercial, reputational, and competitive harm to the Company, compromise trade secret protections, undermine the appeals process, and violate policies meant to protect confidential information under FOIA regulations.","Printed March 19, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-0351-0001_Center_for_Food_Safety_and_Institute_for_Agricultu.pdf,Center for Food Safety and Institute for Agriculture and Trade Policy,"No, they are submitting on their own behalf","21 U.S.C. § 360b, 5 U.S.C. § 553(e), 21 C.F.R. §§ 10.20 and 10.30, 21 U.S.C. § 342",FDA's lack of regulation on the use of antibiotics in distillers grains sold as animal feed,"Prohibit or enjoin the use of antibiotics in the manufacture of distillers grains sold as animal feed for food-producing animals, or alternatively regulate such antibiotics as new animal drugs requiring new animal drug applications","Antibiotics used in ethanol production remain in distillers grains fed to food-producing animals, contributing to antibiotic resistance, posing a public health risk, and violating the Federal Food, Drug, and Cosmetic Act; alternatives to antibiotics are available for ethanol producers; FDA’s failure to regulate is arbitrary and capricious under the APA","Printed March 15, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-0380-0001_University_of_Florida_College_of_Medicine_Jacksonv.pdf,University of Florida College of Medicine - Jacksonville and UNC School of Medicine,Not Applicable,21 C.F.R. 10.30; 21 C.F.R. 25.30; 21 C.F.R. 25.31,FDA’s black box warning on Depot Medroxyprogesterone Acetate (DMPA) labeling regarding loss of bone mineral density and limiting use to two years,Remove the black box warning from the DMPA labeling,"The petition argues that the black box warning was not based on published clinical evidence but rather on an invalid surrogate endpoint (bone mineral density) that does not predict fractures. They claim the warning has harmed public health by discouraging use of a safe contraceptive, and that published studies show bone mineral density recovers after discontinuation without increased fracture risk.","Printed Printed March 28, 2013; Stamped Stamped Apr 2, 2013 "
FDA-2013-P-0408-0001_Chesapeake_Regulatory_Group_Inc_Citizen_Petition.pdf,"Chesapeake Regulatory Group, Inc.",Not Mentioned,"Section 505(b) and 505(j) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 10.25; 21 CFR 10.30; 21 CFR 314.94(a)(3); 21 CFR 25.31",Designation of Reference Listed Drugs (RLDs) for peritoneal dialysis fluids (specifically Baxter Healthcare’s Dianeal PD-2 and Dianeal Low Calcium products),Request FDA to designate specific Baxter Healthcare peritoneal dialysis products as Reference Listed Drugs (RLDs),"The petitioner argues that without designated RLDs, sponsors cannot submit ANDAs for generic versions, and since Baxter’s Dianeal products dominate the market, they are appropriate standards for generic comparisons. This designation would facilitate generic competition and prevent significant variations between generics and brand-name products.","Printed Printed March 29, 2013; Stamped Stamped Apr 3, 2013"
FDA-2013-P-0424-0001_Actelion_Pharmaceuticals_Ltd_Citizen_Petition.pdf,Actelion Pharmaceuticals Ltd.,Not Mentioned,"21 USC 355, 21 CFR 10.30","FDA standards for approving ANDAs for Ventavis or generic iloprost inhalation solutions, addressing sameness of active ingredient (diastereoisomer ratio), formulation equivalency, bioequivalence demonstration, and device compatibility.","(1) the active ingredient has the same ratio of diastereoisomers, (2) any formulation differences are justified with bioequivalence and nebulizer performance data, and (3) the device used does not differ materially from the approved devices (I-neb and Prodose systems).","Ventavis is a complex, locally-acting drug-device combination used to treat pulmonary arterial hypertension. Differences in stereochemistry, formulation, or delivery device could affect safety and efficacy; therefore, strict equivalence in active ingredients, inactive ingredients, and device characteristics is required to ensure therapeutic equivalence and patient safety.","Printed Printed 5 April 2013; Stamped Stamped April 8, 2013"
FDA-2013-P-0426-0001_Shotwell_Carr_Inc_Citizen_Petition.pdf,"Shotwell & Carr, Inc.",Not Mentioned,"Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. § 25.33(d)(5); 21 C.F.R. § 20.61",Suitability determination for an abbreviated new animal drug application (ANADA) for a cyclosporine oral solution for dogs differing from the reference listed drug (ATOPICA®) in dosage form,Request the FDA to determine that a new oral solution form of cyclosporine for dogs is suitable for filing under an ANADA,"An oral solution provides easier administration with accurate dosing using calibrated syringes, improves convenience for veterinarians and pet owners, and maintains the same active ingredient, strength, route of administration, and dosage as the reference product.","Printed Printed April 19, 2013; Stamped Stamped April 22, 2013"
FDA-2013-P-0435-0001_Tobacco_Control_Legal_Consortium__et_al_Citizen_Pe.pdf,Tobacco Control Legal Consortium,"African American Tobacco Control Leadership Council, American Academy of Pediatrics, American Association for Cancer Research, American Cancer Society – Cancer Action Network, American Heart Association, American Legacy Foundation, American Lung Association, American Public Health Association, Americans for Nonsmokers' Rights, Asian Pacific Partners for Empowerment, Advocacy and Leadership (APPEAL), Association for the Treatment of Tobacco Use and Dependence, Campaign for Tobacco-Free Kids, Corporate Accountability International, NAATPN, Inc., National Association of County and City Health Officials, National Latino Alliance for Health Equity, Society for Research on Nicotine and Tobacco, Summit Health Institute for Research and Education, Inc., and Valerie B. Yerger, N.D.","Title 21, Chapter 9, Subchapter V, Part A of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. 10.30; Family Smoking Prevention and Tobacco Control Act (codified at 21 U.S.C. § 387g(a)(1)(A), (3)(A)-(B))",FDA's delay in prohibiting menthol as a characterizing flavor in cigarettes despite the recommendations from the Tobacco Products Scientific Advisory Committee (TPSAC),Petition the FDA to prohibit menthol as a characterizing flavor in cigarettes and cigarette smoke,"Menthol cigarettes increase youth smoking initiation, addiction, and reduce cessation rates, especially among minorities; menthol’s continued availability undermines public health goals and perpetuates tobacco-related health disparities; TPSAC and extensive scientific evidence support that removing menthol would significantly benefit public health","Printed Stamped April 12, 2013; Stamped nan"
FDA-2013-P-0470-0001_Salix_Pharmaceuticals_Inc_Citizen_Petition.pdf,"Salix Pharmaceuticals, Inc.",Not representing another entity; Salix submitted on its own behalf,"Sections 505(j) and 505(q) of the Federal Food, Drug, and Cosmetic Act (FDCA); 21 U.S.C. §§ 355(j) and 355(q); 21 C.F.R. §§ 10.30, 314.94, and 320.21",FDA's Draft Guidance on establishing bioequivalence for extended-release mesalamine products (specifically Apriso®),"Amend the FDA’s existing bioequivalence criteria for mesalamine extended-release capsules (Apriso®) and require bioequivalence testing under fasted and fed conditions in ulcerative colitis patients, inclusion of both 5-ASA and N-Ac-5-ASA plasma analytes, expanded PK parameters, and specific testing related to colonic distribution","Salix argues that the current FDA criteria do not adequately capture the unique delayed- and extended-release properties of Apriso®, the altered pharmacokinetics in ulcerative colitis patients, the significant role of metabolite N-Ac-5-ASA, and the need to ensure equivalent colonic drug delivery, all of which are critical to maintaining therapeutic effectiveness.","Printed Printed March 7, 2013; Stamped Stamped April 18, 2013"
FDA-2013-P-0471-0001_Bayer_HealthCare_Pharmaceuticals_Inc_Ropes_Gray_LL.pdf,Bayer HealthCare Pharmaceuticals Inc.,Ropes & Gray LLP representing Bayer HealthCare Pharmaceuticals Inc.,"Section 505 of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. § 10.30; Sections 505(c)(3)(E)(ii) and 505(j)(5)(F)(ii) of the FDCA",FDA’s historical approach to denying 5-year exclusivity to fixed-dose combinations (FDCs) that include a new active moiety and a previously approved active moiety,"Request that FDA recognize 5-year exclusivity for dienogest, the new active moiety in NATAZIA","Petitioner argues that the FDA’s current practice contradicts the statutory language, Congressional intent, and FDA’s own regulations, and leads to arbitrary, inequitable outcomes that discourage innovation in fixed-dose combinations; they argue Bayer invested 16 years and nearly $200 million developing NATAZIA, and that dienogest as a new active moiety deserves 5-year exclusivity","Printed April 19, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-0503-0001_Nomax_Inc_Citizen_Petition.pdf,"Nomax, Inc.",Not Mentioned,"21 C.F.R. §§ 10.25(a), 10.30, 314.161(a)(3), 21 C.F.R. § 25.31",Determination whether a listed drug (Urocit®-K Powder) was withdrawn for safety or effectiveness reasons,"Request that FDA determine Urocit®-K Powder was not withdrawn for safety or effectiveness reasons and annotate the Orange Book accordingly, or publish a notice if otherwise","The petitioner reviewed approval documents, prescribing information, adverse effect profiles, and literature; found no safety or efficacy concerns; concluded withdrawal was for business and market strategy reasons","Printed Printed April 18, 2013; Stamped Stamped April 25, 2013"
FDA-2013-P-0504-0001_Nomax_Inc_Citizen_Petition.pdf,"Nomax, Inc.",Not Mentioned,"21 CFR 10.30, 21 CFR 25.31",Amendment of the 'Approved Drug Products with Therapeutic Equivalence' list (Orange Book) to designate Urocit®-K Powder (NDA 019647) as a reference listed drug product,Amend the 'Orange Book' to list Urocit®-K Powder as a reference listed drug product,"The petitioner argues that Urocit®-K Powder is a different dosage form (oral solution) from Urocit®-K 15 meq extended release tablets, and due to the distinction between the two, it should be designated as a separate reference listed drug (RLD) to avoid confusion and ensure appropriate generic development.","Printed Printed April 18, 2013; Stamped Stamped April 25, 2013"
FDA-2013-P-0505-0001_Nomax_Inc_Citizen_Petition.pdf,"Nomax, Inc.",Not Representing Another Entity,21 CFR 10.30; 21 CFR 25.31,"Regulatory classification and approval pathway for fluorescein strips, specifically the 1987 Federal Register notice regulating fluorescein strips as drugs rather than medical devices","FDA approval of a suitability petition allowing submission of an abbreviated new drug application (ANDA) for fluorescein strips, citing fluorescein sodium injection as the reference listed drug, despite differences in dosage form, strength, and route of administration","Petitioner argues that fluorescein strips have a long history of safe professional use, deliver much smaller amounts of fluorescein compared to the intravenous solution, are cleared naturally by tears, and that FDA’s prior classification decisions created regulatory uncertainty. Citing fluorescein injection as a reference listed drug would provide a clear and viable regulatory path to compliance.","Printed Printed April 18, 2013; Stamped Stamped April 25, 2013"
FDA-2013-P-0506-0001_Nomax_Inc_Citizen_Petition.pdf,"Nomax, Inc.",Not Representing Another Entity,21 CFR 10.30; 21 CFR 25.31,The regulatory classification and approval status of Urocit®-K Powder (potassium citrate granules) and its listing (or absence thereof) in the FDA's Orange Book as a reference listed drug.,"Nomax, Inc. requests FDA approval to submit an ANDA for potassium citrate effervescent tablets in 10 meq, 20 meq, and a new 25 meq strength, and to designate Urocit®-K Powder as a reference listed drug.","Nomax argues that Urocit®-K Powder was discontinued for reasons unrelated to safety or efficacy, and the proposed effervescent tablets produce a true molecular solution of potassium citrate similar to the powder, ensuring therapeutic equivalence. They also emphasize the historical safe use of potassium citrate oral dosage forms.","Printed Printed April 18, 2013; Stamped Stamped April 25, 2013"
FDA-2013-P-0509-0001_Skadden_Arps_Slate_Meagher_Flom_LLP_Citizen_Petiti.pdf,"Skadden, Arps, Slate, Meagher & Flom LLP",Not Mentioned,"21 U.S.C. § 301 et seq. (Federal Food, Drug, and Cosmetic Act); 21 C.F.R. § 10.30; 21 C.F.R. §§ 25.30 and 25.31",Approval standards for NDAs involving immunosuppressants indicated for maintenance therapy following renal transplantation,"The petitioner requests FDA to require that all new, modified, or reformulated immunosuppressants for renal transplant maintenance therapy successfully complete at least one 12-month, double-blind clinical trial, with limited exceptions where technically infeasible.","The petitioner argues that FDA precedent supports a 12-month trial standard; short-term trials are inadequate for assessing long-term patient and graft survival; non-inferiority trials need longer assessment periods to ensure meaningful results; open-label trials introduce bias; and double-blind trials are a recognized international standard. Thus, 12-month, double-blind trials are necessary to adequately demonstrate efficacy and ensure patient safety.","Printed Printed April 29, 2013; Stamped Stamped April 30, 2013"
FDA-2013-P-0522-0001_Escher_Fund_for_Autism_Citizen_Petition_Redacted_V.pdf,"Jill Escher, Escher Fund for Autism",Not Representing Another Entity,"21 CFR 10.30; 21 U.S.C. § 355-1(b)(3), 21 U.S.C. § 355-1(b)(4), 21 U.S.C. § 355-1(b)(5)",Approval of Diclegis (doxylamine succinate and pyridoxine hydrochloride) as a Category A pregnancy drug and general pregnancy drug labeling regulations,(1) Revoke the March 2013 approval of Diclegis or reclassify it as a Category C drug pending adequate fetal germline safety testing; (2) Revise OTC and prescription drug labeling to warn about potential fetal germline perturbation risks.,"The petitioner argues that fetal germline cells are highly susceptible to disruption by synthetic drugs during early pregnancy, potentially causing multigenerational developmental disorders. Diclegis, used during a critical window of fetal germline development, may impair germline epigenetic programming. Since Diclegis has not been tested for such effects, the petitioner contends that revocation or stronger warnings are necessary to prevent irreversible harm across generations.","Printed Printed April 26, 2013; Stamped Stamped April 30, 2013"
FDA-2013-P-0572-0001_Prometheus_Laboratories_Inc_Citizen_Petition.pdf,Prometheus Laboratories Inc.,Not Representing Another Entity,"Sections 502, 505, and 527 of the Federal Food, Drug, and Cosmetic Act (FDCA); 21 CFR 10.30; 21 CFR 25.31",FDA's lack of clear standards or procedures for developing single shared Risk Evaluation and Mitigation Strategies (REMS) and granting waivers from the requirement for single shared REMS under Section 505-1 of the FDCA,(1) FDA should complete notice and comment rulemaking to establish clear standards and processes for single shared REMS and waivers; (2) FDA should not grant a waiver from the single shared REMS requirement for Lotronex without giving Prometheus notice and an opportunity to participate in the process.,"Prometheus argues that the absence of clear regulatory standards for single shared REMS exposes innovator companies to antitrust scrutiny, product liability risks, and inefficient resource use. It contends that a lack of guidance complicates negotiations between innovator and generic drug companies and potentially delays generic drug entry. Prometheus also emphasizes that without notice and participation rights, sponsors of listed drugs cannot adequately protect their interests or provide critical information to FDA when waivers are considered.","Printed May 10, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-0573-0001_Lupin_Pharmaceuticals_Inc_Citizen_Petition.pdf,"Lupin Pharmaceuticals, Inc.",Not Representing Another Entity,21 CFR 10.25; 21 CFR 10.30; 21 CFR 314.161; 21 CFR 314.162; 21 CFR 25.31,"FDA’s placement of BANZEL® (rufinamide) Tablets, 100 mg into the Discontinued Drug Products section of the Orange Book","Lupin requests that FDA determine that BANZEL® (rufinamide) Tablets, 100 mg was discontinued for reasons unrelated to safety or effectiveness, and confirm that ANDAs referencing BANZEL® 100 mg Tablets are eligible for approval if other legal and regulatory requirements are met.","Lupin argues that BANZEL® (rufinamide) Tablets, 100 mg was likely discontinued for commercial reasons rather than for safety or effectiveness issues, noting the continued marketing of BANZEL® Oral Suspension and the lack of evidence suggesting safety or efficacy concerns. Lupin cites regulatory requirements obligating FDA to make such a determination before approving an ANDA.","Printed Printed May 9, 2013; Stamped Stamped May 10, 2013"
FDA-2013-P-0574-0001_Watson_Laboratories_Inc_Citizen_Petition.pdf,"Watson Laboratories, Inc.",Not Representing Another Entity,"Sections 505 and 505(q) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 10.30",Draft Bioequivalence Guidance for Silodosin Capsules issued in April 2013 and approval standards for ANDAs for generic RAPAFLO® (silodosin) capsules,(1) Refuse to approve any ANDAs for generic RAPAFLO® unless bioequivalence is demonstrated for both silodosin and its active metabolite KMD-3213G using strict statistical evaluation of AUC and Cmax; (2) Revise the Draft Guidance on Silodosin to require strict statistical evaluation for both silodosin and KMD-3213G.,"Watson argues that the active metabolite KMD-3213G significantly contributes to the therapeutic efficacy and safety of RAPAFLO®. Because KMD-3213G has a longer half-life and a substantial pharmacologic role, failing to require bioequivalence testing for this metabolite risks approving non-equivalent generics that could negatively impact patient health, especially among patients with moderate renal impairment.","Printed Printed May 9, 2013; Stamped Stamped May 10, 2013"
FDA-2013-P-0608-0001_Copy_1_of_2_Janssen_Research_and_Development_LLC_R.pdf,"Janssen Research & Development, LLC","Represented by Joy J. Liu, Ropes & Gray LLP","Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355), 21 C.F.R. § 10.30",FDA-2007-D-0369),"FDA should require specific bioequivalence parameters, including partial area under the concentration-time curve (pAUC0–72h and pAUC0–28d), in addition to traditional Cmax, AUC0–t, and AUC0–∞, for review and approval of any proposed generic or follow-on product referencing INVEGA® SUSTENNA®","Traditional bioequivalence metrics (Cmax and AUC) may not detect clinically meaningful differences in drug release profiles, which could impact patient safety and efficacy; differences in particle size distribution could alter release rates; simulation studies demonstrated that switching to generics without these additional bioequivalence measures could result in significant clinical consequences like relapse or side effects due to under- or overexposure to paliperidone.","Printed May 9, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-0615-0001_State_of_California_Department_of_Consumer_Affairs.pdf,California Speech-Language Pathology and Audiology and Hearing Aid Dispensers Board,Not Representing Another Entity,"21 CFR 808.20(c); 21 CFR 801.420; 21 CFR 801.421; 21 CFR 808.1(d)(3); California Business and Professions Code (BPC) Sections 2538.23, 2538.36, 2538.38, 2538.49",Federal preemption of state requirements related to the sale of hearing aids via catalog or direct mail,Request for exemption from federal preemption to allow enforcement of California's stricter requirements regarding hearing aid sales by catalog or direct mail.,"California's requirements provide greater consumer protections, including requiring sellers to be licensed, prohibiting the provision of professional services without direct examination, mandating ear canal observation, requiring a signed verification statement, and extending document retention periods to seven years to support consumer safety and enable investigations into misconduct.","Printed Printed May 30, 2012; Stamped Stamped June 4, 2012"
FDA-2013-P-0631-0001_CorePharma_LLC_Citizen_Petition.pdf,"CorePharma, LLC",Not Representing Another Entity,21 CFR 10.25(a); 21 CFR 10.30; 21 CFR 314.161; 21 CFR 25.31,"Discontinuation of Moban® (molindone hydrochloride) Tablets, NDA 017111, and its listing in the FDA Orange Book","Request that FDA determine that Moban® Tablets were not withdrawn from sale for reasons of safety or effectiveness, and allow submission of an ANDA referencing Moban®","CorePharma asserts that Moban® was discontinued due to sourcing issues rather than concerns regarding safety or effectiveness. The petitioner argues that under FDA regulations, this determination is necessary to permit approval of an ANDA referencing the discontinued drug.","Printed Printed May 22, 2013; Stamped Stamped May 23, 2013"
FDA-2013-P-0664-0001_Watson_Laboratories_Inc_Citizen_Petition.pdf,"Watson Laboratories, Inc.",Not Representing Another Entity,"Sections 505 and 505(q) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 10.25; 21 CFR 10.30; 21 CFR 320.24",Approval standards for ANDAs for generic versions of CRINONE® (progesterone gel) 4% and 8%,(1) Refuse to approve any ANDA for a generic version of CRINONE® unless the sponsor demonstrates bioequivalence through both a pharmacokinetic (PK) study and a clinical endpoint study; (2) Issue draft guidance on bioequivalence requirements for generic progesterone gels similar to the guidance issued for generic ENDOMETRIN®.,"Watson argues that CRINONE® is a locally acting drug where traditional bioequivalence measures (based only on systemic absorption) are inadequate. Bioequivalence should be demonstrated using both PK and clinical endpoint studies to ensure that generics perform similarly at the site of action. This approach would align with FDA’s existing draft guidance for a similar product, ENDOMETRIN®.","Printed Printed June 3, 2013; Stamped Stamped June 4, 2013"
FDA-2013-P-0665-0001_Arnall_Golden_Gregory_LLP_Citizen_Petition.pdf,Arnall Golden Gregory LLP,"Representing an unnamed client (not explicitly stated who the client is, but the petition concerns Sanofi's withdrawn product Intal®)","21 U.S.C. § 355; 21 C.F.R. §§ 10.20, 10.25, 10.30, 314.161","FDA's listing of Intal® (cromolyn sodium) Inhalation Capsule, 20 mg in the Discontinued Drug Product List section of the Orange Book","Request that FDA determine that Intal® was withdrawn from the market for reasons other than safety or effectiveness, thereby permitting abbreviated NDA submissions using Intal® as the reference listed drug (RLD)","The petitioner states there is no evidence suggesting that Intal® was withdrawn for safety or effectiveness reasons and that, therefore, FDA should permit abbreviated applications referencing Intal® under 505(j) of the FD&C Act.","Printed Printed May 23, 2013; Stamped Stamped June 3, 2013"
FDA-2013-P-0666-0001_Mutual_Pharmaceutical_Company_Inc_Citizen_Petition.pdf,"Mutual Pharmaceutical Company, Inc.",Not Representing Another Entity,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 314.93; 21 CFR 25.31",FDA approval standards for ANDAs involving changes to dosage strength relative to the listed drug product,"Request that FDA determine that Piroxicam Capsules, 5mg, is suitable for evaluation and approval under an ANDA, allowing Mutual to submit a supplemental application to its approved ANDA for Piroxicam Capsules, 10mg and 20mg.","The proposed 5mg capsule is dose-proportional to the approved 10mg and 20mg strengths, will use the same formulation, dosage form, route of administration, and will provide a smaller capsule size for patients with swallowing difficulties, maintaining the same therapeutic effect and labeling (except necessary changes such as manufacturer name and 'How Supplied' section).","Printed Printed May 28, 2013; Stamped Stamped May 31, 2013"
FDA-2013-P-0667-0001_American_Clinical_Laboratory_Association_Citizen_P.pdf,American Clinical Laboratory Association (ACLA),Not representing another entity,"Federal Food, Drug, and Cosmetic Act (FDCA), Clinical Laboratory Improvement Act of 1967 (CLIA '67), Clinical Laboratory Improvement Amendments of 1988 (CLIA '88), 21 C.F.R. § 807.65(i), 21 C.F.R. § 493.1253(b)(2)",FDA's intention to regulate Laboratory Developed Tests (LDTs) as devices under the FDCA,Request FDA to refrain from issuing draft or final guidance or a proposed or final rule regulating LDTs as devices and to confirm that LDTs are not devices under the FDCA,"FDA lacks statutory authority to regulate LDTs under the FDCA; LDTs are not 'devices' as defined by the Act; regulation of LDTs under FDCA would conflict with CLIA; regulating LDTs would harm public health by reducing access to critical tests and delaying medical innovation; FDA regulation could cause significant economic repercussions for laboratories; concerns about laboratory regulation should be addressed through amendments to CLIA, not through FDCA regulation.","Printed June 4, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-0670-0001_Altaire_Pharmaceuticals_Inc_Citizen_Petition.pdf,"Altaire Pharmaceuticals, Inc.",Not Representing Another Entity,"Section 505(j) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. §§ 10.20 and 10.30; 21 C.F.R. § 25.31","Designation of reference listed drug (RLD) for Gentamicin Sulfate Ophthalmic Solution, EQ 0.3% base, in the FDA's Orange Book","Request to designate Gentak® Gentamicin Sulfate Ophthalmic Solution, ANDA 064163 (held by Akorn Inc.), as the RLD for purposes of ANDA submissions","The current RLD (ANDA 064048 by Bausch & Lomb) is not Q1Q2 equivalent to the original formulation; Gentak® (ANDA 064163) is Q1Q2 equivalent to the original formulation NDA 050039, which was discontinued. Without designating Gentak® as the RLD, generic applicants cannot pursue ANDA submissions based on the original formulation, effectively shielding Gentak® from competition.","Printed Printed June 4, 2013; Stamped Stamped June 5, 2013"
FDA-2013-P-0671-0001_Lachman_Consultant_Sevices_Inc_Citizen_Petition.pdf,"Lachman Consultant Services, Inc.",Not Representing Another Entity,21 CFR 10.30; 21 CFR 314.161; 21 CFR 314.162,"FDA's listing of PARAFLEX (chlorzoxazone) Tablets, 250 mg in the discontinued drug product section of the Orange Book","Request for the FDA to determine whether PARAFLEX (chlorzoxazone) Tablets, 250 mg was voluntarily withdrawn from sale for reasons of safety or effectiveness, in order to permit approval of ANDAs referencing this product",The petitioner argues there is no evidence that the withdrawal was related to safety or efficacy concerns and suggests the product was discontinued for commercial reasons. A favorable determination would allow the approval of generic versions referencing the discontinued product.,"Printed Printed June 4, 2013; Stamped Stamped June 5, 2013"
FDA-2013-P-0675-0001_Lachman_Consultant_Sevices_Inc_Citizen_Petition.pdf,"Lachman Consultant Services, Inc.",Representing an unnamed client,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 10.30; 21 CFR 25.31",Approval pathway for an ANDA for a modified strength version of Ultracet® (Tramadol Hydrochloride 37.5 mg and Acetaminophen 300 mg Tablets) referencing NDA 021123,Request that FDA determine that Tramadol Hydrochloride 37.5 mg and Acetaminophen 300 mg Tablets is suitable for submission as an ANDA based on a change in strength of the acetaminophen component from 325 mg to 300 mg,"The petitioner argues that reducing the acetaminophen strength does not raise questions of safety or effectiveness because the proposed maximum daily dose (2.4g) is consistent with safe exposure levels, and that FDA has previously approved other products containing 300 mg of acetaminophen in combination therapies. The indication, usage, and labeling would remain otherwise unchanged.","Printed Printed June 4, 2013; Stamped Stamped June 5, 2013"
FDA-2013-P-0693-0001_Center_for_Medicine_in_the_Public_Interest_Citizen.pdf,Center for Medicine in the Public Interest,Not Representing Another Entity,"21 C.F.R. § 10.30; Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; ICH Guideline Q3B(R2); ICH Guideline Q3C(R5); USP General Chapter <467>",Approval of a New Drug Application (NDA) or Supplemental NDA (sNDA) for a liquid formulation of Treanda® (bendamustine hydrochloride),"FDA should refrain from approving any NDA or sNDA for a liquid bendamustine formulation unless and until the applicant demonstrates that (1) degradation products are within acceptable limits, (2) excipient safety is proven (particularly for DMA), and (3) the risk of dosing errors due to higher concentration is addressed.","The petitioner argues that a liquid formulation of Treanda could introduce harmful degradation products not present in the lyophilized form, expose patients to unsafe levels of toxic solvents like DMA, and significantly increase the risk of dosing errors due to a much higher drug concentration, all of which require thorough evaluation before any approval.","Printed Printed June 6, 2013; Stamped Stamped June 7, 2013"
FDA-2013-P-0694-0001_Elite_Laboratories_Inc_Citizen_Petition.pdf,"Elite Laboratories, Inc.",Not Representing Another Entity,21 CFR 314.122; 21 CFR 25.31,Designation and use of a Reference Listed Drug (RLD) for an ANDA application where the original RLD (Drixoral) is unavailable in the marketplace,"Request for FDA to determine that the approved and marketed product under ANDA 078648 (Avanthi, Inc.) is suitable for use as a Reference Listed Drug and to allow its use for a product containing an equivalent active ingredient with a different salt form (pseudoephedrine hydrochloride instead of sulfate).","The originally listed RLD (Drixoral) has been unavailable since 2008, and there is no indication it was withdrawn for safety reasons. The approved ANDA product (Avanthi’s) is marketed and contains equivalent active ingredients. Additionally, the FDA’s OTC monograph states that pseudoephedrine sulfate and pseudoephedrine hydrochloride are equivalent for nasal decongestant and bronchodilator use.","Printed Printed May 31, 2013; Stamped Stamped June 6, 2013"
FDA-2013-P-0695-0001_Steven_A_Zecola_Citizen_Petition_Redacted.pdf,Steven A. Zecola,Not Representing Another Entity,21 CFR 10.30; Part 25.30 of the FDA's Administrative Practices and Procedures,FDA's current drug approval process and clinical trial design as it pertains to the treatment of metastatic cancer,"Request for the FDA to (1) internally examine and modify its practices, regulations, and organizational structure for addressing metastatic cancer, (2) establish a Center for the Treatment of Metastatic Cancer, (3) modify trial design for metastatic cancer by collapsing three trial phases into two, and (4) champion an increase in the federal research budget for metastatic cancer from about 8% to 15% of total cancer research spending.","The petitioner argues that metastatic cancer is responsible for 90% of cancer deaths and that current FDA trial designs are inappropriate for metastatic cancer compounds, which are aimed at delaying metastasis rather than shrinking primary tumors. Current processes discourage investment and progress. Revised trial structures and greater research focus are needed to improve treatment options and societal outcomes.","Printed Printed June 5, 2013; Stamped Stamped June 6, 2013"
FDA-2013-P-0701-0001_Organic_PasturesDairy_Co_LLC_Citizen_Petition.pdf,"Organic Pastures Dairy Company, LLC",Not Represented by Another Entity,"21 C.F.R. 10.25, 10.30, 10.30(j), 10.45(f), 10.20(c)",Denial of the original 2008 citizen petition seeking amendment to 21 C.F.R. 1240.61 (regulation prohibiting interstate sale of raw milk and raw dairy products),"Modify the February 26, 2013 denial to allow interstate delivery, sale, or distribution of raw milk and raw dairy products from the seller’s state to the destination state","Raw milk promotes healthy gut bacteria essential for human health; scientific studies show benefits of raw milk (e.g., reduced asthma, allergies, diabetes risk); existing state regulatory programs ensure safety; FDA treats raw milk unfairly compared to other foods; responsible production standards exist; and modifying the regulation would yield public health, environmental, and economic benefits.","Printed Printed May 31, 2013; Stamped Stamped June 5, 2013"
FDA-2013-P-0703-0001_Center_for_Lawful_Access_and_Abuse_Deterrence_Citi.pdf,"Center for Lawful Access and Abuse Deterrence (CLAAD), with additional signatories from National Association of Drug Diversion Investigators, Ryan’s Cause, and National Family Partnership",No legal representation mentioned; petition submitted directly by organizations,"21 C.F.R. §§ 5.10, 10.30; Stop Tampering of Prescription Pills Act of 2013 (H.R. 486, 113th Cong. § 2(b) (2013))",FDA policies regarding the approval of opioid drug products and the promotion of Medication-Assisted Treatment (MAT),(1) immediately reject NDAs and ANDAs for opioid products lacking predictive or determinative data on abuse deterrence; (2) acknowledge in writing that clinical benefits of MAT include outcomes beyond prolonged abstinence; and (3) prioritize and expedite guidance to industry on effectiveness and abuse-deterrence requirements,"Petitioners justify their request by citing the opioid abuse epidemic, the need for FDA regulatory action aligned with Obama Administration policy promoting abuse-deterrent opioids and MAT, the public health risks associated with approving non-abuse-deterrent opioids, economic impacts of prescription drug abuse, and the necessity for the FDA to support innovation by providing regulatory clarity to pharmaceutical companies.","Printed June 11, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-0711-0001_Allergy_Asthma_Network_Mothers_of_Asthmatics_Citiz.pdf,Allergy & Asthma Network Mothers of Asthmatics (AANMA),"AANMA submitted on its own behalf but is joined by other organizations including AAAAI, AARC, ACAAI, ALAA, ATS, and the COPD Foundation","21 C.F.R. § 10.30; section 505 (21 U.S.C. 355); sections 503(b), 505(d)(1), and 505(d)(4) of the FDCA",FDA's proposed new paradigm 'Using Innovative Technologies and Other Conditions of Safe Use to Expand Which Drug Products Can Be Considered Nonprescription',"Request that FDA exempt asthma and anaphylaxis medications from the proposed new paradigm expanding nonprescription drug access, and maintain these products as prescription-only.","Petitioners argue that FDA's proposal is inconsistent with national guidelines (e.g., NAEPP, NIAID), lacks evidence of safe OTC use for asthma and anaphylaxis drugs, could lead to worse health outcomes, undermines physician-patient care models, and risks increased morbidity and mortality by encouraging reliance on quick-relief medications without physician supervision.","Printed Printed May 15, 2013; Stamped Stamped June 13, 2013"
FDA-2013-P-0761-0001_Poly_Cell_Technologies_LLC___Health_Claim_Petition.pdf,PolyCell Technologies LLC and DKSH Italia Srl,PolyCell Technologies LLC and DKSH Italia Srl are jointly submitting; PolyCell Technologies will serve as the primary correspondent,"Section 403(r)(4) of the Food, Drug, and Cosmetic Act; 21 CFR 101.81; 21 CFR 101.14",Expansion of the 'Soluble Fiber from Certain Foods and Risk of Coronary Heart Disease Health Claim' to include Glucagel barley beta-glucan fiber,"Expand the health claim to include Glucagel barley beta-glucan fiber as an eligible substance under 21 CFR 101.81, and issue an Interim Final Rule allowing labeling pending finalization","The petitioners argue that Glucagel barley beta-glucan fiber meets the FDA's criteria for a health claim because it is safe, provides nutritive value, is associated with reduced risk of coronary heart disease, and has significant supporting scientific evidence from human and animal studies. They also highlight that soluble fiber intake in the U.S. is below recommended levels, and that allowing Glucagel would help increase public intake of beneficial soluble fibers.","Printed January 31, 2013; Stamped nan"
FDA-2013-P-0766-0001_Amedra_Pharmaceuticals_LLC_Citizen_Petition.pdf,Amedra Pharmaceuticals LLC,Not Mentioned,21 USC 355; 21 CFR 10.30,FDA's Draft Guidance on Albendazole bioequivalence requirements,"Request that FDA refrain from approving any ANDA referencing ALBENZA unless the ANDA demonstrates (i) bioequivalence based on systemic levels of both albendazole and albendazole sulfoxide, (ii) includes labeling identical to ALBENZA's labeling, particularly pediatric safety instructions, and (iii) includes simulated use testing showing the tablet can be crushed, chewed, and swallowed safely by young children without posing a choking hazard","Because ALBENZA undergoes significant first-pass metabolism to its active form (albendazole sulfoxide), bioequivalence should be demonstrated on both parent and metabolite; pediatric safety labeling is crucial due to a documented choking hazard; simulated use testing is necessary to confirm generic tablets can be safely administered to young children without increasing choking risk","Printed June 18, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-0767-0001_Ascend_Laboratories_LLC_Citizen_Petition.pdf,"Ascend Laboratories, LLC",Not Representing Another Entity,21 CFR 10.25(a); 21 CFR 10.30; 21 CFR 25.31,Approval of a new oral suspension dosage form for tacrolimus in addition to the currently approved capsule and injection forms under NDA 050708 (PROGRAF),Request FDA to determine that Tacrolimus Oral Suspension is a suitable additional dosage form for NDA 050708 (PROGRAF) and permit submission of an application for this form,"The current capsule formulation is not suitable for pediatric patients and adults with swallowing difficulties. Extemporaneous suspensions currently used are not prepared under CGMP standards, posing safety and efficacy concerns. An FDA-approved suspension would ensure safe, standardized dosing and protect healthcare providers during compounding processes.","Printed Printed June 13, 2013; Stamped Stamped June 18, 2013"
FDA-2013-P-0768-0001_Salus_Pharma_LLC_Citizen_Petition.pdf,"Salus Pharma, LLC",Not Representing Another Entity,21 CFR 10.30; 21 CFR 314.161; 21 CFR 314.162; 21 CFR 25.31,"FDA's determination regarding whether Zefazone (cefmetazole sodium) injection, EQ 1 GM base/vial and EQ 2 GM base/vial was withdrawn for safety or effectiveness reasons","Request that the FDA determine whether Zefazone (cefmetazole sodium) injection, EQ 1 GM base/vial and EQ 2 GM base/vial was voluntarily withdrawn for reasons of safety or effectiveness","Zefazone is currently listed as discontinued in the Orange Book; Pharmacia and Upjohn requested withdrawal of the application, but no evidence suggests withdrawal for safety or efficacy reasons. A determination is necessary to permit ANDA submissions referencing Zefazone as the RLD.","Printed Printed June 17, 2013; Stamped Stamped June 18, 2013"
FDA-2013-P-0769-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,"Lachman Consultant Services, Inc.",Not Representing Another Entity,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 10.20; 21 CFR 10.30; 21 CFR 25.31","FDA approval policies regarding the submission of an Abbreviated New Drug Application (ANDA) for Bendamustine Hydrochloride for Injection, 200 mg/vial","Request FDA to declare that Bendamustine Hydrochloride for Injection, 200 mg/vial, is suitable for submission in an ANDA","The petitioner argues that the proposed drug product is the same as the listed drug (TREANDA) except for a change in total drug content (strength), and that the change will improve convenience and reduce medication errors and healthcare practitioner exposure during reconstitution. The formulation is otherwise identical when reconstituted, and the labeling changes are minimal (only adjusting for strength). The change raises no new questions of safety or effectiveness.","Printed Printed June 18, 2013; Stamped Stamped June 19, 2013"
FDA-2013-P-0775-0001_Hyman_Phelps_McNamara_PC_Citizen_Petition.pdf,"Hyman, Phelps & McNamara, P.C. (on behalf of an unnamed client)",Representing a client (client's name not disclosed),"21 C.F.R. §§ 10.25, 10.30, 314.161, 314.162; Sections 505(j) and 505(w) of the Federal Food, Drug, and Cosmetic Act",Determination regarding whether the 12 mg strength of INVEGA (paliperidone) Extended-release Tablets was withdrawn for safety or effectiveness reasons,Request that the FDA determine that the 12 mg strength of INVEGA was not withdrawn for reasons of safety or effectiveness,"There is no evidence that the 12 mg strength was ever marketed or withdrawn for safety or effectiveness reasons. It was approved but never marketed, and thus should still be eligible for use as a reference product in ANDA submissions for generic versions.","Printed June 25, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-0776-0001_Biotechnology_Information_Institute_Citizen_Petiti.pdf,Biotechnology Information Institute,No representation of another entity; the petitioner is the President of the submitting organization.,"Federal Food, Drug, and Cosmetic Act; Public Health Service Act; 21 CFR 5.10",FDA’s practice regarding biologics nomenclature and public disclosure of biologic product identity information,"Request the FDA to assign unique and biosimilar/(bio)generic-type names/identifiers to biologic products and their active agents, and to disclose sufficient public information to enable understanding of product identity.","The petitioner argues that biologics lack functional non-proprietary names and sufficient public information concerning product identity, leading to ambiguity and potential public health risks; the FDA is the only organization capable of implementing needed changes to nomenclature and public disclosures without significantly new resources or expenditures.","Printed June 21, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-0799-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,"Lachman Consultant Services, Inc.",Submitting on behalf of a client (client not specifically named),"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 10.30; 21 CFR 25.31","Request for approval of a Suitability Petition to allow submission of an ANDA for Griseofulvin Tablets, 187.5 mg and 375 mg, based on the RLD Gris-PEG® 250 mg","Request FDA to declare that Griseofulvin Tablets, 187.5 mg and 375 mg, are suitable for submission as an ANDA referencing Gris-PEG® Tablets, 250 mg","The proposed strengths (187.5 mg and 375 mg) are within the dosing range already described in the RLD's labeling, would provide greater dosing flexibility for pediatric and adult patients, reduce the need for crushing tablets for administration, and help optimize dosing convenience and safety without raising new questions of safety or effectiveness.","Printed Printed June 28, 2013; Stamped Stamped July 1, 2013"
FDA-2013-P-0800-0001_Lachman_Consultant_Sevices_Inc_Citizen_Petition.pdf,"Lachman Consultant Services, Inc.",Representing a client (client's name not disclosed),"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 10.30; 21 CFR 25.31","Approval of a Suitability Petition to allow submission of an ANDA for Dapsone Tablets, 50 mg, based on the RLD Dapsone Tablets USP, 100 mg (ANDA 86-842)","Request FDA to declare that Dapsone Tablets, 50 mg, are suitable for submission as an ANDA referencing the RLD Dapsone Tablets, 100 mg","The 50 mg strength is consistent with dosing instructions in the approved labeling for the RLD, would provide greater flexibility for dosage titration, reduce adverse effects, and does not raise any new questions of safety or effectiveness compared to the approved 100 mg product.","Printed Printed June 28, 2013; Stamped Stamped July 1, 2013"
FDA-2013-P-0813-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,"Lachman Consultant Services, Inc.",Representing a client (client's name not disclosed),"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 10.30; 21 CFR 25.31","Approval of a Suitability Petition to allow submission of an ANDA for Hydrocodone Bitartrate and Acetaminophen Tablets USP, 4 mg/300 mg, 6 mg/300 mg, and 8 mg/300 mg","Request FDA to declare that Hydrocodone Bitartrate and Acetaminophen Tablets USP, 4 mg/300 mg, 6 mg/300 mg, and 8 mg/300 mg are suitable for submission as an ANDA","The petitioner argues that the new strengths offer additional dosing flexibility, allow titration to the lowest effective dose to minimize narcotic exposure, and are consistent with the dosing recommendations of the reference listed drugs. The changes do not raise new questions of safety or effectiveness.","Printed Printed July 2, 2013; Stamped Stamped July 3, 2013"
FDA-2013-P-0830-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,"Lachman Consultant Services, Inc.",Representing a client (client's name not disclosed),"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 10.30; 21 CFR 25.31","Approval of a Suitability Petition to allow submission of an ANDA for Hydromorphone HCl Extended-Release Tablets, 24 mg","Request FDA to declare that Hydromorphone HCl Extended-Release Tablets, 24 mg, are suitable for submission as an ANDA referencing EXALGO (hydromorphone HCl) Extended-Release Tablets, 32 mg","The petitioner argues that the proposed 24 mg strength is consistent with the dosing recommendations of the RLD, provides improved dosing flexibility for titration and tapering, minimizes adverse reactions, and does not raise new questions of safety or effectiveness. The Pediatric Research Equity Act (PREA) requirements are also asserted not to apply to this petition.","Printed Printed July 9, 2013; Stamped Stamped July 10, 2013"
FDA-2013-P-0846-0001_KL_Gates_LLP_Citizen_Petition.pdf,K&L Gates LLP,"Yes, K&L Gates LLP is representing a generic drug manufacturer client (not named specifically)","Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA); 21 C.F.R. § 10.30",FDA's policy requiring ANDA applicants to use U.S.-sourced reference listed drugs (RLD) for bioequivalence studies,Request FDA to permit the client to use KUVAN drug product obtained in Israel as the reference product for bioequivalence studies in support of an ANDA submission,"The petitioner argues that BioMarin, the manufacturer of KUVAN, has implemented a restrictive distribution scheme preventing generic manufacturers from obtaining the U.S.-marketed RLD, and that the KUVAN product marketed in Israel is materially the same as the U.S. product; allowing use of the Israeli product would support generic competition and prevent misuse of the Hatch-Waxman system.","Printed Printed July 10, 2013; Stamped Stamped July 11, 2013"
FDA-2013-P-0847-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,"Lachman Consultant Services, Inc.","Yes, representing a client (client's name not disclosed)","Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 10.30; 21 CFR 25.31",FDA’s policy on allowing a new strength drug product to be submitted through an ANDA pathway,"Request FDA to declare that Tizanidine Hydrochloride Tablets, 8 mg, are suitable for submission in an Abbreviated New Drug Application (ANDA) referencing Zanaflex® (4 mg)","The petitioner argues that the 8 mg strength aligns with the dosing regimen already recommended for the reference listed drug, improves patient convenience by reducing the number of tablets needed per dose, potentially improves patient compliance, and does not raise new questions of safety or efficacy.","Printed Printed July 10, 2013; Stamped Stamped July 11, 2013"
FDA-2013-P-0848-0001_Hyman_Phelps_McNamara_PC_Citizen_Petition.pdf,"Hyman, Phelps & McNamara, P.C.","Yes, representing an unnamed client","Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 10.20(a); 21 CFR 10.30; 21 CFR 314.93",FDA's designation of reference listed drugs (RLDs) in the Orange Book,Request FDA to designate Oxacillin for Injection 1g and 2g in ADD-Vantage Vial (approved under ANDA No. 062737) as a Reference Listed Drug (RLD),"The petitioner argues that the currently designated RLD (Oxacillin for Injection in a Flip-Top Vial) has different packaging and administration routes compared to the ADD-Vantage Vial product, and that without RLD designation for the ADD-Vantage product, generic competition would be shielded. Citing FDA policy, the petitioner contends there is a sound basis for designating the ADD-Vantage product as an additional RLD.","Printed July 11, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-0849-0001_Hyman_Phelps_McNamara_PC_Citizen_Petition.pdf,"Hyman, Phelps & McNamara, P.C.","Yes, representing an unnamed client","Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 10.20(a); 21 CFR 10.30; 21 CFR 314.93",Designation of Reference Listed Drugs (RLDs) in the Orange Book,Request FDA to designate Ampicillin for Injection 1g and 2g in ADD-Vantage Vial (approved under ANDA No. 062738) as a Reference Listed Drug (RLD),"The petitioner argues that the current RLD (Ampicillin for Injection in Flip-Top Vial) is approved for both IM and IV use, whereas the ADD-Vantage Vial product is approved only for IV use in a different container/closure system. Designating the ADD-Vantage Vial as an RLD would promote generic competition specifically for that IV-only product configuration.","Printed July 11, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-0850-0001_Teva_Pharmaceutical_Industries_Ltd_Teva_Respirator.pdf,"Teva Pharmaceutical Industries Ltd., Teva Respiratory, LLC","Teva Respiratory, LLC is a subsidiary of Teva Pharmaceutical Industries Ltd.","21 C.F.R. § 10.30; 21 U.S.C. §§ 355(b)(2), 355(j), and 355(q)",Approval of any Abbreviated New Drug Application (ANDA) or 505(b)(2) Application referencing ProAir® HFA (albuterol sulfate) Inhalation Aerosol,Requesting that FDA refrain from approving any ANDA or 505(b)(2) application referencing ProAir® HFA unless certain conditions regarding dose counters and prevention of canister/actuator mismatches are met,"To ensure safety and efficacy, Teva argues that the presence of a dose counter is critical for patient safety because patients might unknowingly use inhalers past their effective dose limit without it; also stresses the need for in vitro and clinical testing to confirm dose counter functionality and the need to mitigate risks of canister/actuator mismatches to avoid dosing errors.","Printed July 12, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-0862-0001_Spec_Pharma_LLC_Fish_Richardson_PC_Citizen_Petitio.pdf,"Spec Pharma, LLC","Fish & Richardson P.C. representing Spec Pharma, LLC","21 U.S.C. § 355 (Section 505 of the Federal Food, Drug, and Cosmetic Act), 21 C.F.R. § 10.30","The New Animal Drug Application (NADA) for BetaVet submitted by Luitpold Pharmaceuticals, Inc.","Requesting that the FDA refrain from granting approval of the BetaVet NADA until arbitration resolves ownership rights in relevant data, advise the applicant of deficiencies in the NADA, and require the applicant to obtain Petitioner's consent if ownership rights are confirmed.","Petitioner alleges that the BetaVet NADA improperly uses or references data owned by Spec Pharma without authorization, violating FDA policies protecting property rights in data. They argue the ownership of the data is under arbitration and the FDA should not approve the application until the matter is resolved to prevent misappropriation and ensure regulatory compliance.","Printed July 12, 2013; Stamped nan"
FDA-2013-P-0884-0001_Eisai_Inc_Citizen_Petition.pdf,Eisai Inc.,Eisai Inc. is submitting on its own behalf but has a marketing and supply agreement with Arena Pharmaceuticals GmbH for BELVIQ®.,"21 U.S.C. 355(c) and (j); 21 C.F.R. 314.107; 21 C.F.R. 10.30; Controlled Substances Act (CSA); 21 U.S.C. 811; 21 C.F.R. 201.57(a)(2), 201.57(c)(10)(i), and 314.70(b)(2)(v)(C).",The initiation of the five-year New Chemical Entity (NCE) exclusivity period before Eisai could commercially market its products due to pending Controlled Substance scheduling.,"(1) Determine the NCE exclusivity for BELVIQ® to start on June 7, 2013; (2) determine the NCE exclusivity for FYCOMPATm to start on the date it can be commercially marketed; (3) provide a substantive response before FYCOMPATm's scheduling is finalized or within five months.","Eisai argues that FDA incorrectly started the NCE exclusivity periods when products could not yet be legally marketed because Controlled Substance scheduling was incomplete, depriving Eisai of the full exclusivity period intended by Congress, and that this practice is arbitrary, capricious, contrary to law, and undermines innovation incentives.","Printed July 25, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-0885-0001_AMAG_Pharmaceuticals_Inc_Citizen_Petition.pdf,"AMAG Pharmaceuticals, Inc.",Not Representing Another Entity,"21 USC 355, 21 CFR 10.30",Draft Guidance on Ferumoxytol (Dec. 2012) and general FDA standards for approving generic versions of nanoparticle intravenous iron products,Request that FDA (1) refrain from approving any ANDA referencing Feraheme until Nulecit Post-Market Contract Studies confirm adequacy of FDA's standards for generic IV iron approval; and (2) require any generic applicant to demonstrate equivalence using a comparative clinical endpoint study and additional laboratory assays,"Justifications include the complex and incompletely characterized structure of ferumoxytol, inadequacy of plasma/serum measurements to establish bioequivalence, lessons learned from inferior therapeutic equivalence of generic iron sucrose products in the EU, concerns raised in the EMA Reflection Paper, potential public health risks from insufficiently characterized generics, and FDA's own actions soliciting post-market studies for existing generics indicating unresolved scientific concerns.","Printed July 24, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-0886-0001_Arnall_Golden_Gregory_LLP_Citizen_Petition.pdf,Arnall Golden Gregory LLP,Representing Population Council,"21 U.S.C. § 355; 21 C.F.R. §§ 10.20, 10.25, 10.30, and 314.161",Discontinuation of Norplant® II Levonorgestrel Implants (Jadelle®) from the market,"Request for FDA to determine that Norplant® II Levonorgestrel Implants (Jadelle®) was withdrawn from the market for reasons other than safety or effectiveness, allowing it to be used as a Reference Listed Drug (RLD) for 505(b)(2) applications","The petitioner asserts there is no information indicating that the withdrawal was due to safety or effectiveness issues, and thus an NDA may be submitted referencing Norplant® II (Jadelle®) as an RLD.","Printed Printed July 17, 2013; Stamped Stamped July 24, 2013"
FDA-2013-P-0944-0001_Jeffrey_G_Thomas_DBA_Thomas_Law_Company__Citizen_P.pdf,Jeffrey G. Thomas DBA Thomas Law Company,Petition submitted on behalf of Ms. Marteen Moore,"Section 515(g) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. §10.30; 21 C.F.R. §814.82(a)(3); 21 C.F.R. §814.47; 21 C.F.R. §820.198; 21 C.F.R. §814.80; 21 C.F.R. §812.140(a)(2); 21 C.F.R. §812.140(b)(2); 21 C.F.R. §820.90(b)(1); 21 C.F.R. §814.9; 21 C.F.R. §820.90(b)(1); 21 C.F.R. §812.38(d); 21 C.F.R. §814.9(a); 21 C.F.R. §814.9(r); Section 515(g)(1) of the Act; Freedom of Information Act (FOIA)",Conditions of the Pre-Marketing Approval (PMA) for Duraseal® Spinal Sealant,Enforce post-approval conditions including completion of a post-approval study on infection rates; investigation into undisclosed risks; investigation into sponsor's compliance with reporting obligations; revision of labeling and package inserts with stronger warnings (including a black box warning); suspension of the PMA; public hearing on continued violations of procedural and substantive due process,"Ms. Moore suffered paralysis allegedly due to the Duraseal® Spinal Sealant during clinical trials. She claims undisclosed serious risks (such as harmful interactions with non-autologous agents and product swelling), lack of informed consent, suppression of adverse event reports by the sponsor and FDA, incomplete post-approval studies, misrepresentation of product characteristics (blue dye color retention), and violations of due process rights prevented her from proving causation in her lawsuit. She argues that the agency must investigate these issues to protect public health and enforce compliance.","Printed Printed July, 2013; Stamped Stamped Aug 1, 2013"
FDA-2013-P-0945-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,"Lachman Consultant Services, Inc.",Representing a client (name not disclosed),"Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act; 21 CFR 10.30","Suitability petition for Carisoprodol Tablets, 300 mg, based on reference listed drug Soma® (Carisoprodol) Tablets USP, 250 mg","Requesting FDA to declare Carisoprodol Tablets, 300 mg, suitable for submission in an ANDA","The proposed change from 250 mg to 300 mg dosage strength is within the approved dosing range for Soma® (250 mg to 350 mg three times daily and at bedtime), offering greater dosing flexibility without raising safety or effectiveness concerns. The Pediatric Research Equity Act (PREA) does not apply to the petition.","Printed Printed August 2, 2013; Stamped Stamped Aug 5, 2013"
FDA-2013-P-0946-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,"Lachman Consultant Services, Inc.",Representing an unnamed client (not explicitly identified),"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. § 10.30",Suitability petition to allow submission of an Abbreviated New Drug Application (ANDA) for a new drug strength,"Request for the FDA to declare Hydrocodone Bitartrate and Acetaminophen Tablets USP, 2.5 mg/300 mg suitable for submission as an ANDA","The proposed lower strength of hydrocodone bitartrate will provide additional dosing options to healthcare practitioners, enabling more precise pain management while minimizing narcotic exposure, and the proposed change does not raise new safety or efficacy concerns.","Printed Printed August 2, 2013; Stamped Stamped Aug 5, 2013"
FDA-2013-P-0947-0001_Hyman_Phelps_McNamara_PC_Citizen_Petition.pdf,"Hyman, Phelps & McNamara, P.C.",Not Mentioned,"505(j)(2)(c) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. §§ 10.20(a), 10.30, and 314.93",Amendment to the Orange Book designation for Cefdinir for Oral Suspension,Request that FDA designate one of the approved Abbreviated New Drug Applications (ANDAs) listed for Cefdinir for Oral Suspension as an additional Reference Listed Drug (RLD),"The originally designated RLD (OMNICEF) has been discontinued, and the current RLD (Sandoz product) is reportedly no longer available on the market; thus, designating a currently marketed product as an RLD would ensure continued generic competition and availability.","Printed August 5, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-0948-0001_Pharmaceutics_International_Incorporated_Citizen_P.pdf,"Pharmaceutics International, Inc. (Pii)",Not Mentioned,"505(j)(2)(C), 21 C.F.R. § 10.20, 10.30, 314.122",Acceptance of an Abbreviated New Drug Application (ANDA) for Valproic Acid Delayed Release Capsules after discontinuation of STAVZOR® by Banner Pharmacaps,"Request the FDA to determine that Banner Pharmacaps discontinued STAVZOR® (valproic acid delayed release capsules) for reasons unrelated to safety and effectiveness and to accept an ANDA for Valproic Acid Delayed Release Capsules, 125 mg, 250 mg, and 500 mg",Banner Pharmacaps withdrew STAVZOR® from the market for reasons unrelated to safety or efficacy; the petitioner seeks to allow submission of an ANDA for generic versions at the same strengths to ensure availability.,"Printed Printed August 7, 2013; Stamped Stamped Aug 8, 2013"
FDA-2013-P-0949-0001_Reginald_Burgess_Garrett_Skelly_ESQ_Citizen_Petiti.pdf,"Reginald Burgess (petition submitted through attorney Garrett Skelly, ESQ)","Garrett Skelly, ESQ is representing Reginald Burgess","21 CFR 801.109; 21 CFR 890.3420; 21 CFR 890.3500; 21 CFR 820.198; 42 USC 12182; 21 CFR 5.10; section 520(e) and 515(d)(1)(B)(ii) of the Federal Food, Drug, and Cosmetic Act","FDA's classification and labeling requirements for external prosthetic devices, specifically approval orders like K991590 for the C-leg",Amend the approval order for the C-leg device to include 'OVER THE COUNTER USE' in addition to 'PRESCRIPTION' use for external prosthetic devices,"The petitioner argues that external prosthetic devices like the C-leg should not be classified solely as prescription devices because this unjustly restricts access for amputees, violates the Americans with Disabilities Act (ADA), and leads to unnecessary monopolistic practices by companies like Otto Bock. He asserts that the devices are safe enough for over-the-counter sale and that requiring prescriptions enables price gouging and discriminatory practices against amputees, citing Olmstead v. L.C. and Executive Order 13217 in support.","Printed Printed August 6, 2013; Stamped Stamped August 9, 2013"
FDA-2013-P-0990-0001_Corporate_Social_Responsibility_Advocate_Reprieve_.pdf,Corporate Social Responsibility Advocate at Reprieve,No external representation; Reprieve itself is the petitioner,"21 C.F.R. 10.30, 21 U.S.C. §355, §355-1, §372, §393",Use of Reglan in force-feeding detainees at Guantanamo Bay,"Suspend approval of Reglan for force-feeding at Guantanamo Bay, investigate compliance by ANI Pharmaceuticals, Inc., and consider requiring a new REMS submission","Petitioner argues that Reglan has serious side effects (including tardive dyskinesia, depression, suicide risk), that detainees are being administered Reglan without informed consent and potentially for longer than the recommended 12 weeks, and that this practice constitutes an urgent health hazard requiring immediate FDA intervention.","Printed Printed 8 August 2013; Stamped Stamped August 12, 2013"
FDA-2013-P-0995-0001_Hyman_Phelps_McNamara_PC_Citizen_Petition.pdf,"Hyman, Phelps & McNamara, P.C.","Representing Monosol Rx, Inc.",505(q) of the FDCA; 21 C.F.R. §§ 10.20 and 10.30,FDA acceptance and approval process for 505(b)(2) NDAs for buprenorphine/naloxone polymer film products,Request that FDA refuse to file any 505(b)(2) NDA for a buprenorphine/naloxone polymer film product unless it references NDA No. 22-410 (SUBOXONE® sublingual film) and complies with impurity limits for naloxone,Petitioner argues that any 505(b)(2) NDA for a buprenorphine/naloxone film should properly identify the SUBOXONE® film NDA as the listed drug to ensure patent protections are respected and that the impurity limits for naloxone established by FDA are properly applied; this prevents circumvention of patent laws and safeguards public health.,"Printed August 12, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-0996-0001_Piedmont_Animal_Health_Citizen_Petition.pdf,Piedmont Animal Health,Not Mentioned,"Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. 25.15; 21 C.F.R. 25.30(h); 21 C.F.R. 25.21",Approval to file an Abbreviated New Animal Drug Application (ANADA) for a different dosage form than the pioneer product SIMPLICEF® (cefpodoxime proxetil).,Permission to file an ANADA for a soft chewable tablet form of cefpodoxime proxetil instead of the pioneer product's film-coated tablet form.,"The petitioner argues that although the generic product will differ in form (soft chewable versus film-coated tablet) and shape (round versus elliptical or round-rectangular), it will have the same active ingredient, dosage, indications, route of administration (oral), and therapeutic effect as the pioneer product, thus qualifying for a suitability petition.","Printed Printed August 12, 2013; Stamped Stamped August 13, 2013"
FDA-2013-P-0997-0001_Thomas_J_Quinn_Citizen_Petition_Redacted.pdf,Thomas J. Quinn,Not Mentioned,"21 U.S.C. Chapter 9 Subchapter V Part C Section 360kk; 21 CFR Section 1030; 21 U.S.C. 351, 352, 360, 360e-360j, 360hh-360ss, 371, 381",Regulation of performance standards for microwave and radio frequency emitting products (specifically to amend standards to include Nuclear Magnetic Resonance Imaging devices),Amend 21 CFR section 1030 to add section 1030.30 establishing performance standards for Nuclear Magnetic Resonance Imaging systems,"There are currently no specific performance standards in 21 CFR for Nuclear Magnetic Resonance Imaging systems, and such standards are necessary because the health effects of microwave energy on the human body are well known and documented; ensuring regulatory control is essential for safety.","Printed Printed August 9, 2013; Stamped Stamped August 13, 2013"
FDA-2013-P-0998-0001_Millennium_Pharmaceuticals_Inc_Citizen_Petition.pdf,"Millennium Pharmaceuticals, Inc.",No representation of another entity; Millennium is submitting on its own behalf.,"Section 505(q) of the Federal Food, Drug, and Cosmetic Act (FDCA), 21 C.F.R. 10.30, 21 C.F.R. part 314",FDA’s acceptance for filing of a New Drug Application (NDA) by Fresenius Kabi USA for a bortezomib injectable product relying on VELCADE® (bortezomib) for Injection.,"(1) human bioequivalence data from multiple-dose testing proving equivalence to VELCADE, (2) preclinical safety data on boric acid for intravenous and subcutaneous administration, and (3) additional human clinical data as needed; and require Fresenius to reference all sources relied upon for safety.","Petitioner argues that Fresenius’s formulation contains boric acid, which has potential toxicity risks, lacks adequate human testing, and that approval without sufficient human clinical data would endanger patients given the established risks and different formulation compared to VELCADE.","Printed Printed August 12, 2013; Stamped Stamped August 13, 2013"
FDA-2013-P-0999-0001_Consumer_Healthcare_Products_Association_Citizen_P.pdf,Consumer Healthcare Products Association (CHPA),Not Mentioned,"21 C.F.R. Part 330; 21 C.F.R. § 201.66(e); Federal Food, Drug, and Cosmetic Act (FDCA)","Ongoing internal analgesic, antipyretic, and antirheumatic monograph proceedings related to acetaminophen labeling","FDA should publish a statement of enforcement policy expressly permitting manufacturers of single-ingredient acetaminophen OTC drugs to include labeling with dosage instructions for children aged six months to two years, and recommend use of a standardized dosing chart",Lack of dosing information on labels for children aged six months to two years may lead to medication errors; acetaminophen is recognized as safe and effective for this age group by medical associations; FDA advisory committees have recommended inclusion of this dosing information; clear labeling would promote consistency and reduce risk of overdose or misadministration.,"Printed August 15, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-1000-0001_Eclat_Pharmaceuticals_LLC_Patton_Boggs_LLP_Citizen.pdf,"Eclat Pharmaceuticals, LLC","Patton Boggs LLP representing Eclat Pharmaceuticals, LLC","21 C.F.R. § 10.30; Sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act",Marketing of unapproved neostigmine methylsulfate injectable drug products competing with an FDA-approved drug (Bloxiverz®),Requesting FDA to initiate immediate enforcement action requiring removal of unapproved injectable neostigmine methylsulfate products from the market,"Petitioner argues that unapproved products challenge the integrity of the FDA drug approval framework, pose safety risks due to differences in labeling and dosage recommendations, and may violate quality control requirements; also claims that the approved product can meet market demand, minimizing concern about shortages.","Printed August 15, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-1001-0001_Weill_Cornell_Medical_College_Citizen_Petition.pdf,Weill Cornell Medical College,"No representation; petition submitted directly by Marcus M. Reidenberg, M.D., on behalf of Weill Cornell Medical College",21 C.F.R. 10.30,Labeling of nonprescription drug products containing ingredients with anticholinergic or histamine H1 inverse agonist effects,"Request for the FDA to add a warning to the labeling of all nonprescription drug products containing ingredients with anticholinergic or histamine H1 inverse agonist effects, warning about potential confusional states including impaired attention, disorientation, and decreased concentration, especially in older people","The petitioner cites scientific studies, observational studies, and clinical trials showing that drugs with anticholinergic effects cause cognitive impairment, especially in the elderly. They argue that nonprescription drugs with such effects can add to the anticholinergic burden unnoticed, leading to confusional states or delirium, warranting a warning label to inform consumers and prevent harm.","Printed Printed August 12, 2013; Stamped Stamped August 16, 2013"
FDA-2013-P-1002-0001_Zydus_Pharmaceuticals_Inc_Citizen_Petition.pdf,Zydus Pharmaceuticals (USA) Inc.,Not Mentioned,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDC Act); 21 C.F.R. § 314.93; 21 C.F.R. § 10.20; 21 C.F.R. § 10.30","Suitability determination for submission of an Abbreviated New Drug Application (ANDA) for Imatinib Mesylate Tablets, 300 mg strength","Request that FDA determine that Imatinib Mesylate Tablets, 300 mg is suitable for submission in an ANDA",The proposed 300 mg strength is between already approved 100 mg and 400 mg strengths of the reference listed drug (GLEEVEC); it would improve patient compliance by providing an appropriate dosage without the need for splitting tablets; it matches the existing dosage forms and routes of administration; and there are no new safety or efficacy concerns.,"Printed Printed August 13, 2013; Stamped Stamped August 16, 2013"
FDA-2013-P-1055-0001_Actavis_Elizabeth_LLC_Citizen_Petition.pdf,Actavis Elizabeth LLC,Not Mentioned,"21 C.F.R. §§ 10.30 and 314.161; 21 C.F.R. §§ 314.122, 314.161; 21 C.F.R. § 25.31; 21 C.F.R. § 10.30(b)",Determination whether a listed drug has been withdrawn from sale for safety or effectiveness reasons,"Requesting that the FDA determine that SUBUTEX® (buprenorphine hydrochloride) Sublingual Tablets, EQ. 2 mg and 8 mg Base were not voluntarily withdrawn for safety or efficacy reasons","Because there is no evidence of commercial distribution of SUBUTEX® 2 mg and 8 mg Sublingual Tablets, the petitioner requests confirmation that their withdrawal was not for reasons of safety or effectiveness to support an ANDA submission","Printed Printed August 16, 2013; Stamped Stamped August 20, 2013"
FDA-2013-P-1056-0001_Public_Citizen_Citizen_Petition.pdf,"Public Citizen and Neil A. Holtzman, M.D.",Public Citizen is representing itself; Neil A. Holtzman is mentioned as a co-petitioner but no external legal representation is indicated.,"21 U.S.C. Section 355(e)(3), 21 C.F.R. 10.30",The continuation of clopidogrel (Plavix) therapy beyond 12 months following implantation of drug-eluting coronary artery stents.,"Add a black-box warning on clopidogrel and its generic equivalents regarding increased risks of major and minor bleeding beyond 12 months, require an updated FDA-approved Medication Guide, and encourage distribution of a 'Dear Doctor' letter.","Petitioners argue that evidence shows no further reduction in thrombotic cardiovascular events beyond 12 months but continued major bleeding risks, necessitating enhanced warnings to protect patients.","Printed Printed August 21, 2013; Stamped Stamped August 22, 2013"
FDA-2013-P-1058-0001_Citizen_Petition_from_IntelGenx_Corporation.pdf,IntelGenx Corp.,Not Mentioned,"21 C.F.R. 10.30, Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act","Approval and designation of Rizatriptan Oral Film as AB-rated relative to the Reference Listed Drug (RLD), Maxalt-MLT® (Merck, NDA 20-865)","Request for the FDA to designate Rizatriptan Oral Film, upon approval, as AB-rated relative to the RLD Maxalt-MLT®","The petitioner argues that Rizatriptan Oral Film meets FDA’s criteria for therapeutic equivalence because it contains the same active ingredient in the same strength, has similar performance and administration characteristics, is bioequivalent to the RLD, will be adequately labeled, and will be manufactured in compliance with Current Good Manufacturing Practice regulations.","Printed Printed August 21, 2013; Stamped Stamped August 22, 2013"
FDA-2013-P-1061-0001_Navinta_LLC_Citizen_Petition.pdf,Navinta LLC,Not Mentioned,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDC Act); 21 C.F.R. § 314.93; 21 C.F.R. § 10.30",Suitability petition to allow submission of an ANDA for a new dosage form (solution instead of lyophilized powder),"Request FDA to find that Ganciclovir Injection, 500 mg/10 ml (50 mg/mL) solution is suitable for submission as an ANDA","The proposed solution form has the same active ingredient, concentration, route of administration, and therapeutic effect as the reconstituted reference listed drug (RLD) Cytovene®; eliminates the need for reconstitution; no additional investigations needed to demonstrate safety and effectiveness.","Printed Printed August 28, 2013; Stamped Stamped August 29, 2013"
FDA-2013-P-1078-0001_Parnell_Technologies_Pty_Ltd_Citizen_Petition.pdf,Parnell Technologies Pty Ltd,Not Mentioned,"21 CFR §10.30; Federal Food, Drug, and Cosmetic Act Section 512 §360b(n)(3)(A)",Amendment to ANADA 200-541 to delete one route of administration,Allow amendment to delete the intravenous route of administration from the currently approved routes for Gonabreed (gonadorelin 100 µg/mL),The removal of the intravenous route does not pose questions of safety or effectiveness because the product remains indicated for intramuscular administration identical to the pioneer product (Cystorelin®),"Printed Printed August 27, 2013; Stamped Stamped September 3, 2013"
FDA-2013-P-1079-0001_Citizen_Petition_from_Medical_Information_Working_.pdf,Medical Information Working Group (MIWG),"Sidley Austin LLP and Ropes & Gray LLP representing the MIWG members, which include Allergan, Bayer, Boehringer Ingelheim, Eli Lilly, Genentech, GlaxoSmithKline, Johnson & Johnson, Novartis, Novo Nordisk, Pfizer, Purdue Pharma, and Sanofi US","21 C.F.R. § 10.30; also references to 21 U.S.C. § 360(k), 21 U.S.C. § 321(m), 21 U.S.C. §§ 352(n), (r), and 21 U.S.C. § 351(f)(1)","FDA regulations and policies regarding manufacturer dissemination of off-label use information and related communications (responses to unsolicited requests, scientific exchange, communications to payors, dissemination of clinical practice guidelines)","Request for FDA to fully respond to prior citizen petition requests concerning off-label communications, to initiate rulemaking for payor communications and clinical guidelines, and to comprehensively review and revise regulations to align with constitutional and statutory requirements","The petition argues that the FDA’s current regulatory approach to manufacturer communication about off-label uses is outdated, unclear, and unconstitutional under recent First and Fifth Amendment case law (citing Sorrell v. IMS Health, FCC v. Fox, and U.S. v. Caronia). It emphasizes that clearer regulations would benefit public health, respect free speech, and support informed decision-making by patients, providers, and payors.","Printed September 3, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-1080-0001_Reginald_Burgess_Garrett_Skelly_ESQ_Citizen_Petiti.pdf,"Reginald Burgess (submitted through Garrett Skelly, ESQ)","Garrett Skelly, Attorney for Reginald Burgess","21 CFR 820.198, 21 CFR 820.200, 21 CFR 801.109, 21 CFR 890.3420, 21 CFR 890.3500, 42 USC 12182, 21 USC 331(a), 21 USC 360c, 21 USC 360k, 21 USC 829","FDA regulations regarding classification of external prosthetics, particularly the lack of over-the-counter availability and the misuse of 'prescription' labeling","Amend 21 CFR 820.198 to add a new section (a)(4) requiring manufacturers to provide direct access to parts and repair information for external prosthetics to users, ensuring no unnecessary restrictions under internal distribution models unless justified by malfunction or safety concerns","The petitioner argues that external prosthetic devices are incorrectly treated as prescription devices when no prescription restriction legally applies, resulting in discrimination against amputees under the ADA; the prosthetics industry uses distribution models to monopolize service and parts access, forcing users into unnecessary, costly service arrangements and restricting user autonomy in violation of the Americans with Disabilities Act and principles established in Olmstead v. L.C.","Printed Printed August 29, 2013; Stamped Stamped September 4, 2013"
FDA-2013-P-1082-0001_Horizon_Pharma_Inc_Citizen_Petition.pdf,"Horizon Pharma, Inc.",Not Represented by Another Entity,"21 C.F.R. § 10.30, 505(j)(2) of the Federal Food, Drug, and Cosmetic Act",Bioequivalence standards for ANDAs referencing NDA No. 202020 for RAYOS® (prednisone) Delayed-Release Tablets,"Request that FDA require ANDA applicants to demonstrate bioequivalence by showing the same delayed-release profile (lag time and Tmax) and bioavailability (BA) profile after 4 hours, under fed conditions, for generic versions of RAYOS® tablets","RAYOS® tablets are specially formulated with a delayed-release mechanism to synchronize with the circadian rhythm of inflammatory symptoms in diseases like rheumatoid arthritis; generics with different delayed-release mechanisms could have different pharmacokinetic profiles, affecting therapeutic outcomes; thus, strict bioequivalence requirements under fed conditions are necessary to ensure therapeutic equivalence.","Printed Printed September 3, 2013; Stamped Stamped September 4, 2013"
FDA-2013-P-1101-0001_Piedmont_Animal_Health_Citizen_Petition.pdf,Piedmont Animal Health,Not Mentioned,"Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 25.24(a)(8)",Permission to file an Abbreviated New Animal Drug Application (ANADA) for a generic new animal drug differing in dosage form (capsule vs. soft chewable tablet) from the pioneer product,Permission to file an Abbreviated New Animal Drug Application (ANADA) for a soft chewable tablet form of clindamycin hydrochloride instead of a capsule,"The generic product will maintain the same active ingredient, dosage, route of administration, indications, therapeutic effects, and warnings as the pioneer product, differing only in dosage form (soft chewable tablet vs. capsule). Piedmont Animal Health argues that the change does not affect the product's intended use or effectiveness.","Printed Printed May 22, 2013; Stamped Stamped May 24, 2013"
FDA-2013-P-1126-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,"Lachman Consultant Services, Inc.","Not representing another entity; petition submitted on behalf of Lachman Consultant Services, Inc.","Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDC Act), 21 CFR 314.93, 21 CFR §10.20, 21 CFR §10.30",Determination of suitability for submission of an Abbreviated New Drug Application (ANDA) for Capecitabine Tablets in 300 mg and 1000 mg strengths,"Request that FDA determine that Capecitabine Tablets, 300 mg and 1000 mg, are suitable for submission in an ANDA","The new strengths differ only in strength (not in dosage form, route of administration, or intended use) from the approved Reference Listed Drug (XELODA 500 mg and 150 mg); no questions of safety or efficacy are raised; availability of additional strengths would facilitate dosing, increase compliance, and reduce medication errors.","Printed Printed September 6, 2013; Stamped Stamped September 9, 2013"
FDA-2013-P-1127-0001_Tobacco_Control_Legal_Consortium_Citizen_Petition.pdf,Tobacco Control Legal Consortium,"American Academy of Pediatrics, American Cancer Society Cancer Action Network, American Heart Association, American Lung Association, American Public Health Association, Campaign for Tobacco-Free Kids, Legacy, National Association of City and County Health Officials, National Association of Local Boards of Health, and others","Title 21, Chapter 9, Subchapter V, Part A of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. § 10.30; Family Smoking Prevention and Tobacco Control Act (codified at 21 U.S.C. § 387)","FDA's lack of regulation over 'other tobacco products' (OTPs) such as cigars, dissolvables, e-cigarettes, and hookah","Petitioners request that FDA assert jurisdiction over and regulate all tobacco products meeting the Tobacco Control Act's definition, and apply existing cigarette and smokeless tobacco restrictions to those products","The petition argues that unregulated non-cigarette tobacco products present serious public health risks, entice youth, and undermine existing public health measures; asserts that FDA has both the authority and responsibility under the Tobacco Control Act to regulate these products to protect public health","Printed September 3, 2013; Stamped nan"
FDA-2013-P-1128-0001_Teva_Pharmaceutical_Industries_Ltd_Citizen_Petitio.pdf,"Teva Pharmaceutical Industries Ltd. and Teva Neuroscience, Inc.","Teva Neuroscience, Inc. is a subsidiary representing Teva Pharmaceutical Industries Ltd.","21 C.F.R. § 10.30, 21 U.S.C. §§ 355(j) and 355(q)",Approval of any Abbreviated New Drug Application (ANDA) referencing Copaxone® (glatiramer acetate injection),"Requesting FDA to refrain from approving any ANDA referencing Copaxone® unless certain scientific conditions regarding sameness, bioequivalence, and immunogenicity are met","Because Copaxone® is a complex colloidal suspension with two distinct nano-sized polypeptide populations that cannot be fully characterized, Teva argues that generic versions cannot demonstrate sameness, bioequivalence, or immunological equivalence without extensive clinical and non-clinical studies, thus posing potential safety and efficacy risks.","Printed September 12, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-1153-0001_Generic_Pharmaceutical_Association_Citizen_Petitio.pdf,Generic Pharmaceutical Association (GPhA),Not representing another entity; GPhA submitted on its own behalf,"21 C.F.R. § 10.30, Biologics Price Competition and Innovation Act (BPCIA)",FDA policy on International Non-proprietary Naming (INN) for biologics and biosimilars,Implement FDA’s INN naming policy equally for all biologics and allow biosimilars approved under the 351(k) pathway to share the same INN as their reference protein products (RPPs),"Shared INNs would ensure consistency, promote competition, enhance patient access to affordable biologics, and maintain pharmacovigilance without introducing confusion; unique INNs would imply clinical differences where there are none, hinder market competition, create unnecessary regulatory burdens, and potentially compromise patient safety.","Printed September 17, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-1199-0001_CorePharma_LLC_Citizen_Petition.pdf,"CorePharma, LLC",Not Mentioned,"21 CFR 10.25(a), 21 CFR 10.30, 21 CFR 314.161(a)(1)","Determination regarding whether the discontinuation of Skelaxin® 400 mg (NDA 013217) by King Pharmaceuticals, Inc. was due to safety or effectiveness reasons","Request that the FDA determine that Skelaxin® 400 mg was not withdrawn from sale for reasons related to safety or effectiveness, to permit approval of an Abbreviated New Drug Application (ANDA)","The petitioner asserts that Skelaxin® 800 mg remains available under the same NDA and can be divided due to scoring, suggesting the 400 mg dosage form was not withdrawn for safety or efficacy concerns; therefore, FDA should permit ANDA referencing the discontinued drug.","Printed Printed September 19, 2013; Stamped Stamped September 20, 2013"
FDA-2013-P-1202-0001_Olsson_Frank_Weeda_OFW_et_al_Law_PC_Citizen_Petiti.pdf,"Olsson Frank Weeda Terman Matz PC (on behalf of a client, not specifically named)",Olsson Frank Weeda Terman Matz PC is representing an unnamed client (not specified in document),"505(j)(2)(C), 21 C.F.R. §§ 10.20, 10.30, 314.93","Requesting FDA action to allow submission of an ANDA for a new strength of an approved drug (Vancomycin Hydrochloride For Injection, USP, Fliptop Vial For Intravenous Use)","Determine that Vancomycin Hydrochloride USP, 1.5 grams (base)/vial is suitable for ANDA submission as a new strength","The petitioner argues that the proposed product will have the same active ingredient, concentration after reconstitution, route of administration, dosage, and indications as the reference listed drug (RLD), differing only in total drug content, and that it would benefit clinical dosing without raising safety or effectiveness concerns.","Printed Printed September 26, 2013; Stamped Stamped September 27, 2013"
FDA-2013-P-1203-0001_McGuireWoods_LLP_Citizen_Petition.pdf,McGuireWoods LLP,Representing an unnamed client (not disclosed in the petition),"505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. §§ 10.30 and 314.93",Suitability determination for submission of an Abbreviated New Drug Application (ANDA) for a different fill volume of Ropivacaine Hydrochloride Injection,The petitioner requests that the FDA determine that Ropivacaine Hydrochloride Injection 2mg/mL in a 500 mL infusion bag is suitable for submission as an ANDA,"The petitioner argues that the proposed product differs from the reference listed drug (NAROPIN) only in total fill volume (500 mL vs. 200 mL), with no change in concentration, active ingredient, dosage form, route of administration, or indications; further, it improves patient and hospital convenience, reduces risk of error and contamination, and decreases pharmacy workload and waste.","Printed Printed September 25, 2013; Stamped Stamped September 26, 2013"
FDA-2013-P-1283-0001_Horizon_Pharma_Inc_Citizen_Petition.pdf,"Horizon Pharma, Inc.",Not Mentioned,"21 C.F.R. § 10.30; Section 505(j)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act); 21 C.F.R. §§ 314.127(a)(7) and 314.127(a)(6)(i); 21 CFR 320.1(e) and 320.23(b)",Approval process for Abbreviated New Drug Applications (ANDAs) referencing RAYOS® (prednisone) delayed-release tablets as the reference listed drug (RLD),"Require that any ANDA referencing RAYOS® must demonstrate (1) no release of prednisone until approximately four hours after intake (equivalent lag time and Tmax) and (2) equivalent bioavailability (BA) profile after the four-hour delay, under fed conditions","RAYOS® tablets employ a unique delayed-release mechanism synchronized with the circadian rise in pro-inflammatory cytokines, critical for therapeutic effect in inflammatory diseases like rheumatoid arthritis; differing delayed-release mechanisms (e.g., enteric coating) could result in different pharmacokinetic profiles, impacting efficacy; thus, bioequivalence must demonstrate equivalent lag time, Tmax, and BA under fed conditions to ensure comparable therapeutic effect.","Printed Printed October 4, 2013; Stamped Stamped October 17, 2013"
FDA-2013-P-1286-0001_Proctor_Gamble_Company_Citizen_Petition.pdf,The Procter & Gamble Company,Not Mentioned,"21 C.F.R. § 10.30, 21 C.F.R. Part 314, 21 U.S.C. §§ 351 and 355","Approval and labeling standards for over-the-counter proton pump inhibitors (PPIs), particularly related to Prilosec OTC and pending applications like Nexium OTC","(1) Continue requiring consistent labeling standards for all OTC PPIs similar to Prilosec OTC; (2) Impose rigorous standards on pending or future OTC PPI applications; (3) Require clinically significant evidence if label differences are proposed, and prevent false or misleading claims about relative safety or efficacy","P&G argues that different labeling among similar OTC PPI products could mislead consumers into thinking certain products are more effective without adequate substantiation, potentially violating the Administrative Procedure Act by treating similarly situated products differently; therefore, consistent class labeling or consistent regulatory standards are necessary to avoid consumer confusion and ensure fair competition.","Printed Printed October 11, 2013; Stamped Stamped October 17, 2013"
FDA-2013-P-1287-0001_Aptalis_Pharma_US_Inc_Citizen_Petition.pdf,"Aptalis Pharma US, Inc.",No representation; Aptalis submitted directly.,"Sections 505 and 505(q) of the Federal Food, Drug, and Cosmetic Act (FDC Act); 21 C.F.R. §§ 10.25 and 10.30","Approval standards for Abbreviated New Drug Applications (ANDAs) for generic versions of Canasa® (mesalamine) Rectal Suppositories, 500 mg and 1000 mg","(1) Refuse to receive or approve any ANDA for a generic Canasa® unless bioequivalence is demonstrated through a clinical endpoint study; (2) Withdraw current bioequivalence guidance and issue new guidance requiring such study; (3) Require assessment of critical quality attributes, including Q1, Q2, Q3 sameness and dissolution testing; (4) Hold final approvals in abeyance until ongoing FDA studies are completed and reviewed.",Aptalis argues that systemic pharmacokinetic data are inadequate to demonstrate bioequivalence for locally acting rectal suppositories like Canasa®; clinical endpoint studies are necessary due to the drug’s local action; significant variability in systemic absorption exists; and critical quality attributes (like spreadability and irritation potential) must be properly assessed to ensure therapeutic equivalence.,"Printed Printed October 15, 2013; Stamped Stamped October 17, 2013"
FDA-2013-P-1288-0001_National_Advocates_for_Pregnant_Women_Citizen_Peti.pdf,National Advocates for Pregnant Women (NAPW),Not representing another entity; submitted directly by NAPW along with support from various individuals and organizations,"21 C.F.R. § 10.30; references also to 21 U.S.C. § 355, 21 U.S.C. § 355(o)(4), 21 U.S.C. § 355-1(b)(3), 21 C.F.R. § 201, 21 C.F.R. § 25.31","FDA's neonatal opioid withdrawal syndrome (NOWS)-related labeling changes for extended-release and long-acting (ER/LA) opioid analgesics announced on September 10, 2013","Petitioner requests the FDA to refrain from implementing NOWS-related labeling changes, remove references to NOWS as life-threatening, modify full prescribing information regarding opioid dependence treatment during pregnancy, and present supporting literature to an advisory committee for evaluation","The petitioner argues that the NOWS-related warnings are medically inaccurate, not supported by substantial evidence, misleading, inconsistent with expert consensus, likely to result in denial of appropriate treatment for pregnant women, and may lead to punitive child welfare interventions against women receiving opioid substitution therapy","Printed Printed October 7, 2013; Stamped Stamped October 17, 2013"
FDA-2013-P-1289-0001_National_Advocates_for_Pregnant_Women_Citizen_Peti.pdf,National Advocates for Pregnant Women (NAPW),,21 C.F.R. § 10.35; 21 C.F.R. § 10.30; 21 U.S.C. § 355(o)(4); 21 C.F.R. § 201.56(a)(2); 21 C.F.R. § 201.56(a)(3); 21 U.S.C. § 355-1(b)(3); 21 U.S.C. § 355-1(b)(4)(A); 21 U.S.C. § 355-1(b)(4)(B); 21 U.S.C. § 355(d)(5); 21 U.S.C. § 355(d)(7); 21 U.S.C. § 355(e); 42 C.F.R. § 8.12(g)(1); 42 C.F.R. § 8.12(e)(3),"The FDA's neonatal opioid withdrawal syndrome–related labeling changes for extended-release and long-acting opioid analgesics announced on September 10, 2013",An indefinite stay of implementation of the NOWS-related labeling changes for ER/LA opioid analgesics,"The warnings are medically inaccurate and unsupported by substantial evidence, conflict with FDA labeling requirements and expert consensus, risk discouraging necessary pain and addiction treatments for pregnant women, and may lead to harmful child welfare interventions","Printed Printed October 7, 2013; Stamped Stamped October 17, 2013"
FDA-2013-P-1290-0001_FDA_CDER_Response_to_Hogan_Lovells_US_LLP_Petition.pdf,National Advocates for Pregnant Women (NAPW),,21 C.F.R. § 10.35; 21 C.F.R. § 10.30; 21 U.S.C. § 355(o)(4); 21 C.F.R. § 201.56(a)(2); 21 C.F.R. § 201.56(a)(3); 21 U.S.C. § 355-1(b)(3); 21 U.S.C. § 355-1(b)(4)(A); 21 U.S.C. § 355-1(b)(4)(B); 21 U.S.C. § 355(d)(5); 21 U.S.C. § 355(d)(7); 21 U.S.C. § 355(e); 42 C.F.R. § 8.12(g)(1); 42 C.F.R. § 8.12(e)(3),"The FDA’s neonatal opioid withdrawal syndrome–related labeling changes for extended-release and long-acting opioid analgesics announced on September 10, 2013",An indefinite stay of implementation of the NOWS-related labeling changes for ER/LA opioid analgesics,"The NOWS-related warnings are medically inaccurate, unsupported by substantial evidence, conflict with FDA labeling requirements and expert consensus, risk discouraging necessary pain and addiction treatments for pregnant women, and may lead to harmful child welfare interventions","Printed 7-Oct-13; Stamped Stamped October 31, 2013"
FDA-2013-P-1291-0001_American_Herbal_Products_Association_Citizen_Petit.pdf,American Herbal Products Association (AHPA),"AHPA represents companies that market herbs, herbal and botanical products, and other health-related products regulated by the FDA",21 C.F.R. § 10.30; 21 C.F.R. Part 111; 21 C.F.R. Parts 110 & 111; 21 U.S.C. § 704(b); 21 C.F.R. § 25.30; 21 C.F.R. § 10.30(b),FDA policy in the Inspections Operations Manual prohibiting investigators from quoting or citing cGMP regulations in Form FDA-483 inspectional observations,Formally rescind the policy prohibiting investigators from quoting or citing cGMP regulations in 483s and revise the Inspections Operations Manual to require that 483s reference each relevant cGMP regulation,"Because omission of regulatory citations slows resolution of compliance issues, undermines agency transparency, forces industry to guess at regulatory requirements, and inclusion of citations would promote understanding, compliance, transparency, and harmonize FDA policies without imposing additional work","Printed Printed October 17, 2013; Stamped Stamped October 18, 2013"
FDA-2013-P-1292-0001_Sun_Pharmaceutical_Industries_Ltd_Winston_Strawn_L.pdf,"Sun Pharmaceutical Industries, Ltd.","Winston & Strawn LLP representing Sun Pharmaceutical Industries, Ltd.","21 U.S.C. § 301 et seq.; 21 C.F.R. § 10.30; 21 C.F.R. § 25.31(a),(c); 21 C.F.R. § 10.30(b); 21 U.S.C. § 331(a); 21 C.F.R. § 201.5; 21 C.F.R. § 201.128",The FDA approval and labeling of Ganirelix Acetate Injection indication regarding use as a female contraceptive,Confirm that Ganirelix is not approved by the FDA for use as a female contraceptive and that the FDA-labeled indication for Ganirelix is not equivalent to a method of female contraception,"To correct misleading legal positions by Organon suggesting Ganirelix is approved as contraception, to prevent off-label marketing and misbranding, and to protect public health by clarifying approved use","Printed October 17, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-1294-0001_Luitpold_Pharmaceuticals_Inc_Citizen_Petition.pdf,Sheppard Mullin Richter & Hampton LLP,"Yes; representing Luitpold Pharmaceuticals, Inc.","21 U.S.C. § 301 et seq.; 21 C.F.R. § 10.30; 21 C.F.R. §§ 25.30(h), 25.31(a); 21 C.F.R. § 10.30(b)","The FDA’s approval and labeling of injectable iron products for treatment of iron deficiency anemia outside of chronic kidney disease (e.g., NDA 203565 for Injectafer®)","Require that any NDA or NDA supplement for injectable iron products for IDA outside CKD be approved only if pivotal studies include an objective oral iron run-in demonstrating intolerance or unsatisfactory response, and require contraindications for patients with prior allergic reactions to iron products or multiple drug allergies","Because of significant safety risks of injectable iron, the need to restrict use to patients objectively intolerant or unresponsive to oral iron, to avoid arbitrary approval practices, and to protect hypersensitive patients from serious allergic reactions","Printed Printed September 30, 2013; Stamped Stamped October 1, 2013"
FDA-2013-P-1296-0001_Lannett_Company_Inc_Citizen_Petition.pdf,"Lannett Company, Inc.",,21 U.S.C. § 355(j); 21 C.F.R. § 314.93; 21 C.F.R. § 25.31(a),The requirement under FDCA 505(j) and 21 C.F.R. § 314.93 that an ANDA match the dosage form of the RLD,That the Commissioner determine an ANDA for Acetazolamide Extended-Release Tablets may be submitted using DIAMOX® SEQUELS® (capsules) as the RLD,Both the RLD capsules and proposed tablets are solid oral dosage forms with the same route and are expected to have the same therapeutic effect under identical conditions of use,"Printed Printed October 2, 2013; Stamped Stamped October 4, 2013"
FDA-2013-P-1297-0001_Harmony_Cone_Ear_Candles_Citizen_Petition.pdf,Kevin Boulton,Yes; representing the families of Harmony Cone Ear Candles,21 U.S.C. § 321(h) (FDCA § 201(h)); 21 C.F.R. § 10.30; 21 C.F.R. § 101.93(g)(2),The FDA’s classification of Harmony Cone Ear Candles as medical devices under FDCA § 201(h),"Issue a declaratory order that HCEC are not medical devices under FDCA § 201(h), hold a public hearing, and temporarily stay any enforcement actions against HCEC manufacturers, distributors, or sellers during pendency","Because HCECs fall outside the device definition (not recognized in USP/NF, not intended for medical use, no chemical action, not metabolized), are safe relaxation products with no adverse event reports, and consumers have a right to use them free from unwarranted FDA enforcement","Printed Printed September 26, 2013; Stamped Stamped September 30, 2013"
FDA-2013-P-1373-0001_Terry_L_Tennant_Citizen_Petition_Redacted.pdf,Terry L. Tennant,,"Federal Food, Drug, and Cosmetic Act; Public Health Service Act; 21 C.F.R. § 5.10; 21 C.F.R. § 804.3(d)",The definition of 'distributor' in the device-tracking regulations (21 C.F.R. Part 804),Amend 21 C.F.R. § 804.3(d) (and related sections) to expand the definition of 'distributor' to cover any person who furthers marketing of a device from the original manufacturer's installation or importation to the ultimate user,"Because devices sold off the device master record after initial installation or importation are not currently tracked, creating gaps that undermine patient safety and the FDA’s ability to locate devices for notification or recall","Printed Printed September 19, 2013; Stamped Written October 17, 2013"
FDA-2013-P-1374-0001_Citizen_Petition_from_Pharmacists_Planning_Service.pdf,"Pharmacists Planning Services, Inc.",,"21 C.F.R. § 10.20; 21 C.F.R. § 10.30; 21 C.F.R. § 5.10; Federal Food, Drug, and Cosmetic Act; Public Health Service Act",The FDA’s failure to hold public hearings and establish updated regulatory standards on cellphone radiation exposure (SAR and RFR/EMF),Hold public hearings; open a federal registry; modernize federal cellphone radiation standards; require 12-point warning labels; educate consumers on reducing exposure,"Emerging scientific evidence links RFR/EMF and cellphone use to health risks (glioma, acoustic neuroma, behavioral disorders, autism, etc.); IARC classification as possible carcinogen; need to protect vulnerable populations and inform consumers of precautions","Printed October 4, 2013; Stamped nan"
FDA-2013-P-1375-0001_Purdue_Pharma_LP_Kleinfeld_Kaplan_and_Becker_LLP_C.pdf,Purdue Pharma L.P.,"Kleinfeld, Kaplan and Becker LLP representing Purdue Pharma L.P.","21 C.F.R. §§ 10.30, 314.53, 314.94, 314.127; 21 C.F.R. Part 320; Section 505 and Section 505(j) of the FDCA (21 U.S.C. § 355); 5 U.S.C. § 706(2)(A); 21 C.F.R. § 25.31; 21 C.F.R. § 10.30(b)","FDA’s development of guidance and standards for approving generic versions of reformulated OxyContin, including acceptance or approval of ANDAs citing OxyContin and the draft bioequivalence guidance on oxycodone ER tablets","Adopt a guidance specifying comparative in vitro and in vivo abuse-deterrence tests for generic OxyContin, refuse to approve any ANDA that lacks or fails these tests, and revise the draft bioequivalence guidance accordingly","Generic products without equivalent abuse-deterrent attributes would pose higher abuse risk and a different risk–benefit profile, so rigorous testing is needed to protect public health and to meet FDCA and APA requirements","Printed Printed October 21, 2013; Stamped Stamped October 22, 2013"
FDA-2013-P-1376-0001_Covis_Pharma_Sarl_Buchanan_Ingersoll_Rooney_PC_Cit.pdf,Covis Pharma Sarl,Submitted by the law firm Buchanan Ingersoll & Rooney PC on behalf of Covis Pharma Sarl,"Section 505(j) of the FDCA (21 U.S.C. § 355(j)); 21 C.F.R. §§ 10.20, 10.30, 314.108, 25.31(a)",FDA’s handling of Lanoxin (digoxin) Tablets NDA 20-405—specifically the Agency’s listings in the Orange Book and its policies on approving ANDAs and recognizing marketing exclusivity for the 0.0625 mg and 0.1875 mg strengths,"Confirm that those two strengths were never fully approved in 1997, that their three-year exclusivity therefore never ran, and that Covis now holds a full three-year marketing exclusivity period for them beginning with FDA’s October 17 2013 PAS approval","Because FDA required a PAS, new draft labeling, CMC dissolution data, and a prior-approval inspection before allowing marketing, the two strengths were not fully approved or marketed; exclusivity awarded in 1997 could not have started, so Covis is entitled to the full three-year term now to protect its investment and ensure consistent regulatory treatment","Printed October 21, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-1377-0001_Covis_Pharma_Sarl_Buchanan_Ingersoll_Rooney_PC_Cit.pdf,"Buchanan Ingersoll & Rooney PC (Edward John Allera, Barbara Binzak Blumenfeld, Tina Hu)",Law firm submitting on behalf of Covis Pharma Sarl,"§ 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355(j)); 21 C.F.R. § 10.20; 21 C.F.R. § 10.30; 21 C.F.R. Part 320",FDA’s practice of allowing waivers of dissolution and blend-uniformity testing for generic digoxin tablets under its bioequivalence guidance,"Require every ANDA for 0.0625 mg and 0.1875 mg digoxin tablets referencing Lanoxin to perform and pass dissolution and blend-uniformity validation testing, and deny any waiver requests for those tests","Digoxin is a narrow-therapeutic-index drug with extremely high excipient-to-API ratios, making dissolution and blend uniformity critical to safety and bioequivalence; FDA compelled Covis to perform these tests before marketing, so equal treatment, public health protection, and due-process fairness demand the same requirements for all generic sponsors","Printed October 21, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-1379-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,"Lachman Consultant Services, Inc.",Representing a client (client name not disclosed),"21 C.F.R. § 10.30, 21 C.F.R. § 314.161, 21 C.F.R. § 314.162, 21 C.F.R. § 25.31","Determination whether PREZISTA® (darunavir) Tablets, 400 mg, has been voluntarily withdrawn from sale for safety or effectiveness reasons","Request FDA to determine if PREZISTA® (darunavir) Tablets, 400 mg, was withdrawn for safety or efficacy reasons to enable action on an ANDA",Janssen announced discontinuation of the 400 mg dosage strength for commercial reasons favoring the 800 mg strength; no evidence of safety or efficacy concerns related to the withdrawal.,"Printed Printed October 21, 2013; Stamped Stamped October 22, 2013"
FDA-2013-P-1397-0001_UCB_Inc_Citizen_Petition.pdf,"UCB, Inc.","No third-party representation; UCB, Inc. submitted the petition directly.","505(j) of the FDCA, 21 C.F.R. §10.30, 21 U.S.C. §355(c)(3)(E), 21 U.S.C. §355(j)(5)(F), 5 U.S.C. §801(a)(1)(A), 21 C.F.R. §314.101(d), 21 C.F.R. §314.108(a), 21 C.F.R. §314.105(a), 21 C.F.R. §314.70(b)(2)(v)(C), 21 C.F.R. §201.57(a)(2)",Timing of triggering new chemical entity (NCE) exclusivity relative to Drug Enforcement Administration (DEA) scheduling under the Controlled Substances Act (CSA),"(1) Determine that NCE exclusivity for lacosamide began on June 9, 2009 (instead of October 28, 2008) and will end on June 9, 2014; (2) Confirm that approval of certain ANDAs will be stayed until December 7, 2016; (3) Respond substantively to this petition within 150 days.",UCB lost 223 days of NCE exclusivity because lacosamide could not be legally marketed until it was scheduled under the CSA; exclusivity should start from the date the drug could be legally marketed to preserve the full 5 years intended by statute; FDA's current practice undermines incentives for innovation and causes inequitable treatment for sponsors of scheduled drugs.,"Printed Printed October 21, 2013; Stamped Stamped October 22, 2013"
FDA-2013-P-1398-0001_Novartis_Group_Citizen_Petition.pdf,Novartis Group of Companies,Not Mentioned,21 C.F.R. § 10.30,"Policy regarding naming of biosimilars (i.e., whether biosimilars should share the same international nonproprietary name (INN) as the reference product)",Require that a biosimilar be identified by the same international nonproprietary name (INN) as the reference product,"Assigning unique INNs to biosimilars would cause unnecessary confusion, undermine established FDA practices, harm pharmacovigilance, confuse healthcare providers, misrepresent regulatory decisions about biosimilarity and interchangeability, and create barriers to patient access to affordable biologics.","Printed October 28, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-1399-0001_Sigmapharm_Laboratories_LLC_Citizen_Petition.pdf,"Sigmapharm Laboratories, LLC",Not Mentioned,"Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355), 21 C.F.R. Part 314, 21 C.F.R. § 10.30",Acceptance and filing standards for Abbreviated New Drug Applications (ANDAs) for Asenapine Maleate Sublingual Tablets,"Request that FDA refuse to receive (RTR) any ANDA for Asenapine Maleate Sublingual Tablets that does not include a bioequivalence study performed per FDA’s June 2013 product-specific bioequivalence guidance, and to set the filing date for 180-day exclusivity based on submission of a complying study","Sigmapharm argues that FDA issued specific bioequivalence guidance for Asenapine Maleate Sublingual Tablets in June 2013, that this guidance was necessary for patient safety and study reliability, that there was enough time to comply before the NCE-1 date, and that allowing non-compliant applications would be inequitable to those who followed FDA guidance","Printed Printed October 30, 2013; Stamped Stamped October 31, 2013"
FDA-2013-P-1505-0001_Teva_Respiratory_LLC_Teva_Citizen_Petition.pdf,"Teva Respiratory, LLC (on behalf of Teva Pharmaceutical Industries Ltd.)","Teva Respiratory, LLC is submitting on behalf of Teva Pharmaceutical Industries Ltd.","21 C.F.R. § 10.30, Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355)","FDA's policy regarding the inclusion of integrated dose counters on rescue inhalers (both brand and generic), and approval standards for such products",Refrain from approving any new rescue inhalers (brand or generic) unless they include an integrated dose counter; 2. Implement a plan to transition currently approved rescue inhalers without a dose counter to versions with integrated dose counters,"Integrated dose counters are critical to patient safety because they allow patients and caregivers to accurately track the amount of medication remaining in rescue inhalers, reducing risks of inhaler failure during life-threatening asthma attacks; studies show dose counters reduce emergency room visits, improve asthma control, and the FDA’s previous encouragement for dose counters has been insufficiently enforced.","Printed November 15, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-1507-0001_Dr_S_Albert_Edwards_Citizen_Petition_Redacted.pdf,"Dr. S. Albert Edwards, PharmD, RAC, FRAPS",No representation of another entity; petitioner states no business interest in a CRSO.,"Prescription Drug Amendments to the Federal Food, Drug, and Cosmetic Act; 21 CFR Parts 312 & 314; 21 CFR 5.10; 21 CFR 25.34; 21 CFR 10.30(e)(2).",FDA Office of Business Informatics' handling of webtrader accounts for Contract Research/Service Organizations (CRSOs) submitting eCTDs for sponsors.,Uniformly institute a policy allowing single webtrader accounts for all CRSOs rather than requiring separate accounts for each sponsor.,"Closing single accounts is disruptive; multiple accounts create unnecessary business burdens, risk wrong account selection leading to errors, will increase workload as eCTD/RPS submissions become mandatory, and will strain FDA resources especially under staffing limitations.","Printed Printed September 30, 2013; Stamped Stamped October 17, 2013"
FDA-2013-P-1508-0001_Cadence_Pharmaceuticals_Inc_Craig_Pharma_Solutions.pdf,"Craig Pharma Solutions LLC on behalf of Cadence Pharmaceuticals, Inc.","Craig Pharma Solutions LLC is representing Cadence Pharmaceuticals, Inc.","505(b), 505(j), 505(q) of the FDCA; 21 C.F.R. § 10.30",Approval of ANDAs or 505(b)(2) NDAs for intravenous acetaminophen solutions differing in inactive ingredients from Ofirmev®,FDA is requested to refrain from approving any ANDA or 505(b)(2) application for an acetaminophen solution for injection that does not have the same inactive ingredients as Ofirmev® unless supported by evidence from nonclinical studies and adequate and well-controlled clinical trials showing comparable safety and efficacy,"Because aqueous acetaminophen solutions are chemically unstable, changes in inactive ingredients could compromise product stability, safety, and effectiveness by increasing hydrolysis and oxidation, leading to unknown degradants with potential toxicity; thus, differences must be justified with appropriate clinical and nonclinical evidence.","Printed November 4, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-1509-0001_Dr_S_Albert_Edwards_Citizen_Petition_Redacted.pdf,"Dr. S. Albert Edwards, Pharm.D., RAC, FRAPS",No representation of another entity; petitioner is an individual submitting on their own behalf,"Prescription Drug Amendments to the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. Part 314; 21 C.F.R. 5.10; 21 C.F.R. 10.30; 21 C.F.R. 25.34",Development and harmonization of electronic Common Technical Document (eCTD) Module 1 between the U.S. FDA and Health Canada,Request for the FDA to meet with Canada's Health Products and Food Branch (HPB) to craft a common Module 1 for the eCTD/RPS submissions,Facilitating easier electronic submissions between the U.S. and Canada; reducing the administrative burden for companies filing in both countries; supporting regulatory harmonization due to geographic proximity; and acknowledging unique FDA-specific requirements that would remain separate,"Printed Printed October 27, 2013; Stamped Stamped November 4, 2013"
FDA-2013-P-1510-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,"Lachman Consultant Services, Inc.",Representing an unnamed client,"21 C.F.R. 10.30, 21 C.F.R. 314.161, 21 C.F.R. 314.162, 21 C.F.R. 25.31",Determination of whether a listed drug has been voluntarily withdrawn for safety or effectiveness reasons,"Request the FDA to determine that the Lupron Depot-Ped dual vial products were voluntarily withdrawn for reasons other than safety or effectiveness, to enable ANDA submissions, and to annotate the Orange Book accordingly",Petitioner argues that the withdrawal was not due to safety or effectiveness concerns but rather because Abbvie shifted to a different packaging configuration; no evidence of safety or efficacy problems found in public domain or court records,"Printed Printed November 4, 2013; Stamped Stamped November 5, 2013"
FDA-2013-P-1511-0001_PetaStrip_LLC_Citizen_Petition.pdf,"PetaStrip, LLC",Not Mentioned,"Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 520.1193(d)(2)(ii); 21 CFR 25.30(h)",Suitability Petition for a different dosage form (soluble film) of an approved pioneer animal drug product,Request for permission to file an Abbreviated New Animal Drug Application (ANADA) for a soluble film dosage form differing from the pioneer product Heartguard® for Cats,"The proposed generic product (soluble film) has the same active ingredient, dosage, administration route, indications, and therapeutic effect as the pioneer chewable product; it only differs in dosage form, does not raise new safety or effectiveness questions, and thus meets the criteria for a Suitability Petition under the law.","Printed November 1, 2013; Stamped Stamped November 7, 2013"
FDA-2013-P-1512-0001_PetaStrip_LLC_Citizen_Petition.pdf,"PetaStrip, LLC",Not Mentioned,"Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 25.30(h); Section 512(n)(1)(E) of the Act",Suitability Petition for approval of a different dosage form for a generic animal drug,"Permission for PetaStrip, LLC to file an Abbreviated New Animal Drug Application (ANADA) for a soluble film dosage form instead of the chewable tablet form of the pioneer product Heartguard®","The proposed generic product would have the same active ingredient (ivermectin), dosage, route of administration, and therapeutic effect as the pioneer product, differing only in dosage form; prior FDA approvals of soluble film dosage forms (e.g., Suboxone®, Onsolis®) are cited as precedent; bioequivalence requirements will be satisfied and labeling differences are minimal.","Printed November 1, 2013; Stamped Stamped November 7, 2013"
FDA-2013-P-1515-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,"Lachman Consultant Services, Inc.","Lachman Consultant Services, Inc. submitted on behalf of a client (name not disclosed).","21 C.F.R. § 10.30, 21 C.F.R. § 314.161, 21 C.F.R. § 314.162, 21 C.F.R. § 25.31","Determination whether ZOVIRAX® (acyclovir sodium) for Injection, eq. 1 g base/vial, was withdrawn for safety or efficacy reasons.","Request for FDA to determine whether ZOVIRAX® (acyclovir sodium) for Injection, eq. 1 g base/vial, was voluntarily withdrawn from sale for safety or efficacy reasons.","The drug is listed in the Orange Book’s discontinued section, and the petitioner believes it was discontinued for commercial reasons rather than safety or efficacy concerns. This determination is needed to proceed with an ANDA referencing the drug.","Printed Printed November 15, 2013; Stamped Stamped November 18, 2013"
FDA-2013-P-1516-0001_Spectron_mrc_LLC_Citizen_Petition.pdf,"Spectron mrc, LLC","No, Spectron mrc, LLC is submitting on its own behalf",21 U.S.C. 355(j)(7); 21 CFR 314.161; 21 CFR 314.162,Determination regarding whether Sodium Pertechnetate Tc-99m (technetium Tc-99m sodium pertechnetate) was withdrawn from sale for reasons of safety or effectiveness,"Issue a notice stating that Sodium Pertechnetate Tc-99m was not withdrawn from sale for reasons of safety or effectiveness, allowing approval of ANDAs referring to this drug","To alleviate shortages caused by decreased global nuclear reactor output, to assist in national efforts to reduce the use of highly enriched uranium, and because historical withdrawal was not due to safety or effectiveness concerns","Printed Printed November 19, 2013; Stamped Stamped November 21, 2013"
FDA-2013-P-1552-0001_Citizen_Petition_from_Hearing_Industries_Associati.pdf,Hearing Industries Association (HIA),Not representing another entity; the petitioner is HIA itself,"Section 513(e) of the Federal Food, Drug, and Cosmetic Act (FDC Act); 21 C.F.R. § 860.123",FDA’s classification of wireless air conduction hearing aids as Class II devices,Reclassify wireless air conduction hearing aids possessing specific features from Class II to Class I,Wireless air conduction hearing aids with certain features (ear-to-ear communication and wireless streaming) have been safely used for decades without incident; current general controls are sufficient for safety and effectiveness; no evidence of risk from electromagnetic exposure; amplification functionality remains independent even if wireless features fail; standard safety protocols and EMC compliance are already practiced by manufacturers.,"Printed November 21, 2013; Stamped nan"
FDA-2013-P-1554-0001_Sigmapharm_Laboratories_LLC_Citizen_Petition.pdf,"Sigmapharm Laboratories, LLC",Not representing another entity,"Section 505 and 505(q) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 355), 21 C.F.R. Part 314, 21 C.F.R. § 10.30",Acceptance or refusal to receive Abbreviated New Drug Applications (ANDAs) for Asenapine Maleate Sublingual Tablets based on compliance with FDA's June 2013 product-specific bioequivalence guidance,FDA should consider incomplete and refuse to receive any ANDA for Asenapine Maleate Sublingual Tablets that does not contain bioequivalence study results conforming to the June 2013 guidance; filing acceptance date should be based on compliance with the guidance,"Sigmapharm argues that allowing non-complying ANDAs disadvantages companies that submitted complete applications, could cause inequitable 180-day exclusivity determinations, and that sponsors had enough time to complete studies based on the June 2013 guidance; FDA's own RTR guidance supports refusing non-complying studies","Printed Printed November 26, 2013; Stamped Stamped November 27, 2013"
FDA-2013-P-1606-0001_Citizen_Petition_from_Pharmacists_Planning_Service.pdf,"Pharmacists Planning Services, Inc. (PPSI)","PPSI is representing itself but works in conjunction with National Coalition Against Prescription Drug Abuse (NCA-PDA), Marin County Pharmacists Drug Abuse Task Force (MCPDATF), and Marin County Pharmacists Association (MCPhA)","21 CFR 10.20, 21 CFR 10.30, Federal Food Drug and Cosmetic Act (FDA Act), 21 CFR 1306.04, Health and Safety Code Section 11153",FDA regulatory decisions regarding reformulation of opioid drug products and implementation of standards for pharmacists regarding hydrocodone schedule II products,Requesting FDA to add drug-abuse deterrent technology to all hydrocodone schedule II products and to implement standards of practice and corresponding responsibilities for pharmacists,"Petitioners argue that prescription drug abuse, especially opioid abuse, is a public health epidemic; hydrocodone products are heavily prescribed and abused; FDA has previously acted to deter abuse with other opioids; pharmacists have a professional duty to help prevent inappropriate use; standards for prescription monitoring programs (PMPs) should be federally mandated to assist in preventing drug diversion and abuse","Printed Printed November 25, 2013; Stamped Stamped November 26, 2013"
FDA-2013-P-1609-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,"Lachman Consultant Services, Inc.","Lachman Consultant Services, Inc. is representing an unnamed client.","21 C.F.R. 10.30, 21 C.F.R. 314.161, 21 C.F.R. 314.162, 21 C.F.R. 25.31",FDA's determination whether the two-vial container closure system used for Lupron Depot and Lupron Depot-PED Injection drug products was withdrawn for reasons of safety or effectiveness.,"Requesting the FDA to determine that the two-vial container closure system for Lupron Depot and Lupron Depot-PED Injection drug products was not withdrawn for reasons of safety or effectiveness, and to enable ANDA submissions referring to the two-vial system as the Reference Listed Drug.","The petitioner argues that the two-vial system was discontinued voluntarily and not due to safety or effectiveness concerns, citing lack of evidence from trade press, court cases, or FDA actions suggesting otherwise.","Printed Printed November 25, 2013; Stamped Stamped November 26, 2013"
FDA-2013-P-1611-0001_Citizen_Petition_from_Clarissa_Clarke___Redacted.pdf,Clarissa Clarke,Not Applicable,"Federal Food, Drug, and Cosmetic Act Subchapter A Part 10 Subpart B Section 10.20; Title 21 CFR Part 872",Amendments to regulations within Title 21 CFR Part 872—Dental Devices (specifically §§ 872.3690 and 872.6070),"Amend §§ 872.3690 and 872.6070 to include Special Controls Guidance concerning material properties, performance reporting, energy requirements for polymerization, and reporting for dental curing lights","Incomplete polymerization of tooth shade resin materials can lead to restoration failure, increased dental treatment costs, and patient dissatisfaction. Current labeling and information provided with dental materials and curing lights do not sufficiently ensure safe and effective polymerization. Amending the regulations would provide dentists with critical information necessary to optimize curing and material performance, ultimately improving patient outcomes and reducing healthcare costs.","Printed Printed November 26, 2013; Stamped Stamped December 2, 2013"
FDA-2013-P-1614-0001_Citizen_Petition_from_Alliance_of_African_Shea_Ass.pdf,Alliance of African Shea Associations (AASA),Sidley Austin LLP representing the Alliance of African Shea Associations (AASA),"Section 401 of the Federal Food, Drug, and Cosmetic Act (FDCA), 21 U.S.C. § 341; 21 C.F.R. §§ 163.123, 163.124, 163.130","Standards of identity for chocolate (specifically sweet chocolate, milk chocolate, and white chocolate) prohibiting alternatives to cacao fat",Amend the standards of identity for chocolate to allow the optional use of shea-based ingredients (blends of sheanut oil and palm oil) as alternatives to cacao fat,"Shea-based blends have similar triglycerides and physical properties to cacao fat, preserving the basic nature and essential characteristics of chocolate; the change would support economic opportunities for West African women, harmonize U.S. standards with international regulations, and align with FDA's modernization initiatives without negatively impacting consumer expectations or product quality.","Printed Printed November 5, 2013; Stamped Stamped November 15, 2013"
FDA-2013-P-1623-0001_Sigmapharm_Laboratories_LLC_Citizen_Petition.pdf,"Sigmapharm Laboratories, LLC",Not representing another entity; petition submitted on behalf of Sigmapharm itself,"505, 505(q) of the FDCA (21 U.S.C. § 355), 21 C.F.R. Part 314, 21 C.F.R. § 10.30","Acceptance and filing standards for Abbreviated New Drug Applications (ANDAs), specifically for Asenapine Maleate Sublingual Tablets","Request that the FDA refuse to receive (RTR) any ANDA for Asenapine Maleate Sublingual Tablets that does not contain bioequivalence study results compliant with FDA’s June 2013 product-specific bioequivalence guidance, and base exclusivity eligibility on the submission date of a compliant ANDA","Sigmapharm argues that allowing non-compliant ANDAs would be inequitable to applicants who submitted complete and compliant applications on the designated filing date, potentially impacting 180-day exclusivity rights, and that FDA’s own RTR guidance and bioequivalence standards mandate adherence to the issued June 2013 bioequivalence requirements","Printed Printed December 6, 2013; Stamped Stamped December 8, 2013"
FDA-2013-P-1636-0001_Citizen_Petition_from_Lannett_Company_Inc.pdf,"Lannett Company, Inc.","Not representing another entity; Lannett Company, Inc. is the petitioner.","Sections 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDCA), 21 CFR § 314.93, and 21 CFR § 25.31(a).",Submission and approval process for Abbreviated New Drug Applications (ANDAs) differing from the Reference Listed Drug (RLD) in active ingredient strength.,"The petitioner requests the FDA to determine that ANDAs may be submitted for Hydromorphone Hydrochloride Tablets, 1 mg (scored tablets) and Hydromorphone Hydrochloride Oral Solution, 1 mg per 5 mL.","The petitioner argues that the changes in strength do not pose safety or efficacy concerns because the dose, use, and route of administration are identical to the RLD; elderly and geriatric patient references support the therapeutic need for lower doses; and existing approved doses in the RLD package insert suggest the safety and utility of lower strength formulations.","Printed Printed December 4, 2013; Stamped Stamped December 9, 2013"
FDA-2013-P-1637-0001_Attachment_1_Alemtuzumab_The_Eagle_Has_Landed_In_E.pdf,The Eagle Has Landed in Europe').,Not mentioned.,None cited.,The document does not comment on an FDA action; it is a medical article discussing the approval and clinical use of Alemtuzumab for multiple sclerosis in Europe.,None requested.,Not applicable since this is an informational/clinical article and not a citizen petition.,Printed Not explicitly stated in the document.; Stamped nan
FDA-2013-P-1640-0001_Citizen_Petition_from_Hyman_Phelps_and_Mcnamara_PC.pdf,"Hyman, Phelps & McNamara, P.C.","The submitting entity (Hyman, Phelps & McNamara, P.C.) is representing an unnamed client.","505 of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. §§ 10.25 and 10.30",FDA regulations for Over-the-Counter (OTC) Transdermal Nicotine Patches (TNPs) regarding labeling and safety,"Require the sponsors of all OTC TNPs to include permanent, smudge-resistant product identifying labeling on the backing membrane to help avoid accidental pediatric exposures to nicotine.",Accidental pediatric exposures to nicotine from OTC TNPs are increasing and can have serious health consequences; permanent product identification on patches would help avoid accidental exposure and assist healthcare professionals in emergencies.,"Printed December 5, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-1641-0001_Citizen_Petition_from_TEVA_Pharmaceuticals.pdf,"Teva Pharmaceutical Industries Ltd. and Teva Neuroscience, Inc.","Teva Neuroscience, Inc. is a subsidiary representing Teva Pharmaceutical Industries Ltd.","21 C.F.R. § 10.30, 21 U.S.C. §§ 355(j) and 355(q)",FDA approval of any Abbreviated New Drug Application (ANDA) referencing Copaxone® (glatiramer acetate injection),"Requesting that FDA refrain from approving any ANDA referencing Copaxone® unless certain conditions are met, including proof of identical active ingredient, comparable immunogenicity, and bioequivalence via clinical studies","Teva argues that due to the complexity and immunogenicity of Copaxone®, and the limitations of current analytical technologies, it is not possible to definitively establish sameness of the active ingredient without extensive clinical testing, and that approval without meeting these stringent standards could compromise safety and efficacy","Printed December 5, 2013; Stamped Same Date both printed and stamped"
FDA-2013-P-1654-0001_Gordon_Johnston_Regulatory_Consultants_LLC_Citizen.pdf,"Gordon Johnston Regulatory Consultants, LLC",Representing an interested party (name not specified),"21 CFR 10.30, 21 CFR 314.161, 21 CFR 314.162, 21 CFR 25.31","Determination whether Leucovorin Calcium Injection-Preservative Free, 10 mg/mL, 10 mL total fill volume (ANDA 40147) has been withdrawn for reasons of safety or efficacy","Requesting FDA to determine if Hospira's Leucovorin Calcium Injection-Preservative Free, 10 mg/mL, 10 mL total fill volume (ANDA 40147) has been voluntarily withdrawn or withheld from sale for reasons of safety or efficacy",Because the product appears in the Discontinued Section of the Orange Book and a determination is needed before any ANDA referencing it can be approved; regulatory requirement under 21 CFR 314.161(a)(1),"Printed Printed December 13, 2013; Stamped Stamped December 17, 2013"
FDA-2013-P-1710-0001_Citizen_Petition_From_Noven_Pharmaceuticals_Inc.pdf,"Noven Pharmaceuticals, Inc.",No representation of another entity; submitting on its own behalf,"505(q) of the Federal Food, Drug, and Cosmetic Act, 21 C.F.R. § 10.30",Approval of Abbreviated New Drug Applications (ANDAs) for generic Daytrana® (Methylphenidate) Transdermal System,"Refuse to approve any ANDA for a generic version of Daytrana® unless the ANDA sponsor conducts a usability study in adults, adolescents, and children under 'real world' conditions demonstrating non-inferior patch adhesion performance compared to Daytrana® TDS","Patch detachment risks efficacy loss and safety concerns (e.g., accidental exposure to children); real-world adhesion issues not adequately captured by current bioequivalence and in vitro tests; FDA acknowledged importance of real-world usability studies particularly for pediatric patients; need to ensure therapeutic equivalence and public health safety","Printed Printed December 23, 2013; Stamped Stamped December 24, 2013"
FDA-2013-P-1711-0001_Citizen_Petition_From_Morgan_Lewis_Bockius_LLP.pdf,"Morgan, Lewis & Bockius LLP",Unnamed client (representation details not disclosed),"21 U.S.C. § 505, 21 U.S.C. § 811 et seq., 21 C.F.R. § 10.30, 21 C.F.R. Part 300 et seq., 21 C.F.R. Part 1300 et seq.",FDA's plan to recommend to HHS to reclassify hydrocodone combination products from Schedule III to Schedule II,Request that hydrocodone combination products containing less than 5 mg of hydrocodone remain in Schedule III and not be rescheduled to Schedule II,"Upscheduling lower-strength hydrocodone products would burden vulnerable patient populations (e.g., chronic pain, hospice, palliative care patients) by limiting access to needed medications, increase healthcare burdens, and would not effectively curb drug misuse and abuse; maintaining lower-strength products in Schedule III strikes a balance between control and accessibility.","Printed Printed December 26, 2013; Stamped Stamped December 27, 2013"
